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Pre-eclampsia (PE) is a devastating condition that affects 5-8% of pregnant 
women and is the leading cause of fetal and maternal deaths worldwide. The etiology 
of this disorder, however, is largely unknown. The BPH/5 mouse model is the only 
known rodent model that spontaneously develops the symptoms of PE as well as many 
of the placental pathologies associated with the human condition. As the pathogenesis 
of PE is known to start before the symptoms begin, this disease is very difficult to 
study in women.  As such, this mouse model is invaluable in examining early 
pregnancy events and elucidating the pathophysiology of this disorder.  
 Angiogenic factors have been promising biomarkers of PE in women. We 
found that the angiogenic profile in BPH/5 mice mimics that of women at high risk of 
developing PE with a decrease in the pro-angiogenic factors vascular endothelial 
growth factor (VEGF) and related placental growth factor (PGF). Using a viral gene 
transfer strategy to increase systemic levels of one of these important angiogenic 
factors, VEGF, we provide evidence of a functional link between diminished VEGF 
levels and the hallmark symptoms of PE in BPH/5 mice. 
 The BPH/5 model of PE also exhibits significant fetal demise throughout 
pregnancy. One third of conceptuses are lost by mid gestation.  To further characterize 
early pregnancy events in BPH/5, we used ultrasound to score embryos based on their 
health status.  We were able to detect evidence of developmental challenge in vivo in a 
subset of embryos prior to previous necropsy data.  Using fetoplacental units with 
varying development/health status, we performed gene expression microarray studies 
to examine the molecular cues to fetal demise in this model.   Challenged fetoplacental 
units show dysregulation in functional pathways related to angiogenesis, development 
and apoptosis. 
 Finally, as the placenta plays a pivotal role in the development of PE, and the 
BPH/5 model shows marked placental abnormalities, we examined whether these 
placental defects in BPH/5 could be traced to the peri-implantation period when this 
organ is established. We found significant pre-implantation embryo maturation delay 
along with premature maternal endocrine signaling in BPH/5 mice, suggesting 
asynchronous timing of these important events involved in implantation. This was 
accompanied by implantation defects as indicated by abnormal spacing of 
implantation sites, as well as morphological and molecular abnormalities in early 
BPH/5 implantation sites compared to controls.  Using a protocol to artificially 
synchronize implantation events in BPH/5, we were able to rescue the implantation 
clustering defect, the molecular dysregulation in early implantation sites, and 
importantly, several later placental abnormalities including placental expansion toward 
the decidua and umbilical blood flow.   
 The research in this thesis highlights and confirms the important role of 
angiogenic factors in successful and healthy pregnancies, provides clues to the 
molecular signature that may underlie fetoplacental defects associated with PE, and 
sheds new light on early peri-implantation events that may set the stage for the 
development of PE and perhaps other disorders of pregnancy.   
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1.1 Pre-eclampsia 
1.1.1 Hallmarks, definitions and associated disorders 
Pre-eclampsia (PE) is serious pregnancy associated syndrome that affects 3-
14% of pregnancies worldwide and has a recurrence rate of 7.5-65%1.  Despite 
improvements in peri-natal care, the incidence of PE continues to rise, as described in 
the 2009 National Vital Statistics report (www.cdc.gov). It is a heterogeneous and 
multi-organ disorder that is the leading cause of maternal and fetal deaths in both 
developing and developed countries.  The hallmark symptoms include new onset 
hypertension >140mmHg systolic blood pressure (BP) and >90mmHg diastolic BP in 
women who had normal BP prior to 20weeks gestation, and proteinuria ≥0.3gm in 
24hr urine collection, or ≥30mg/dL of random urine determination (≥1 + reading on 
dipstick)2.  Additional symptoms can include headache, blurred vision, abdominal pain 
and edema.  Some cases of severe PE can also be accompanied by the HELLP 
syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets). If left untreated, pre-
eclampsia can progress to eclampsia which involves cerebral vasospasms resulting in 
tonic-clonic seizures and even death.  PE is distinct from gestational hypertension, 
where hypertension is the only symptom. Women with gestational hypertension are 
often closely monitored for the early detection of PE and its more life threatening 
associated symptoms of HELLP and eclampsia. 
 Though pre-eclampsia has been documented in medical literature for hundreds 
of years, the treatment remains minimal.  The problem lies in the unknown etiology of 
the disease.  Without understanding the mechanism and pathological progression of 
the disease, it is difficult to both diagnose early, and devise a treatment strategy.  
Clinicians are left to manage the symptoms of PE once the syndrome has started.  
Treatment trials with dietary supplementation with Vitamins C and E have proven 
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largely ineffective at reducing the risk of development of PE with even an increase in 
risk of gestational hypertension, severe pre-eclampsia, eclampsia and HELLP3, 4.  
Today, women with severe-pre-eclampsia are put on strict bed-rest. If the symptoms 
of pre-eclampsia become too threatening to maternal health, the fetus (and placenta) is 
delivered.  As a result, pre-eclampsia is directly responsible for 15% of pre-mature 
births each year in the US (www.pre-eclampsia.org).  
 Pre-eclampsia is a disease tremendously heterogeneous in its symptomology, 
organs involved and timing of the onset of these symptoms.  Women can exhibit 
symptoms of PE as early as 28 weeks, while others do not show symptoms until term. 
The hallmark symptoms of PE, including new onset hypertension and proteinuria, are 
exhibited with all women independent of timing of onset. Yet some women go on to 
develop HELLP syndrome, have low-birthweight babies or poor neonatal outcomes, 
whereas other PE mothers deliver healthy birthweight babies with the maternal 
symptoms resolving soon after delivery.  With the expansion in research in this area 
over the past 25 years, the overarching diagnosis of PE has shifted to reflect the many 
classifications of this syndrome.   Early onset PE has symptoms beginning prior to 34 
weeks gestation and is often complicated with more severe placental pathology, poor 
fetal outcomes, and more extreme maternal complications such as HELLP and 
eclampsia5-7. Late onset PE pregnancies show symptoms later than 34 weeks gestation 
and are often less severe, with symptoms resolving after delivery of usually a healthy 
weight neonate5-7.  Placenta samples from early and late onset PE reveal a very 
different pathological origin7, 8. Additionally, the delivery of a small-for-gestational-
age baby reflects a complication know as Intrauterine Growth Restriction (IUGR).  Up 
to one third of PE pregnancies are associated with IUGR9, 10.  Importantly, IUGR is not 
unique to PE pregnancies, as 8-14% of normal pregnancies are also affected11. It is 
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now becoming more widely accepted that though early and late onset PE as well as 
IUGR result from dysfunction of many of the same pathways, the etiology of these 
conditions is unique, and should be examined with this in mind.   
1.1.2 Epidemiology : Risk Factors and Trends 
Pre-eclampsia is recognized to have both a placental component as well as a 
maternal component.  Many of the placental abnormalities are shared between PE and 
IUGR, and yet some women go on to have asymptomatic pregnancies with IUGR, 
whereas others develop PE. What has long been referred to as maternal 
“constitutional” factors12 have been more itemized with the help of retrospective 
clinical analysis. Women that are at higher risk of developing PE have the following 
pre-dispositions: obesity13, diabetes14, hyperhomocysteinemia15, and black  
ethnicity12, 16.  Additionally, women with prior history of hypertension are at a ~20% 
risk of developing PE, and approximately a 30% risk of having a small-for-gestation-
age fetus17.  Interestingly, when one combines three risk factors of chronic 
hypertension, obesity and previous PE pregnancy, the risk of developing PE only 
increases to 23% and the risk for a small-for-gestation-age fetus remains the same17.  
This highlights what a large risk factor chronic hypertension is to the development of 
this disorder.  
Though less well examined, PE is known to have some hereditary and thus 
genetic links.  With prior PE pregnancies, mothers, daughters, sisters and 
granddaughters are at a 2-5 fold increased frequency of PE compared to the control 
population18-20.  Despite the major and obvious contribution of the maternal genome, 
fetal genes, and therefore the paternal genome are also implicated in the development 
of this syndrome20.  Sons born to PE pregnancies are at an increased rate of fathering 
their own children in pregnancies complicated with PE 20.  With such multifactorial 
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disease such as PE, determining the loci responsible for eliciting this syndrome would 
be both beneficial for genetic screening of prospective parents, but ultimately a very 
daunting task. 
1.1.3 The causative organ of PE 
Pre-eclampsia is a disease whose etiology is closely tied to the placenta. In fact, it 
is only upon delivery of the placenta that symptoms of PE resolve. PE is known to 
affect molar pregnancies21, 22, a pregnancy disorder in which no fetus is present, 
implicating the placenta as the sole causative organ in this disorder. 
1.2 A Disease of Theories 
1.2.1 The two-stage model: 
In an effort to begin to understand the multifactorial basis for the development 
of PE, Roberts and colleagues developed the paradigm of pre-eclampsia as a two stage 
disorder23. Within this framework, the first stage of the disease, referred to as Stage 1, 
reflects defects in placentation, whereas Stage 2, reflects the maternal syndrome, or 
the where the symptoms of PE manifest in the mother.   
Stage 1: Placentation and alterations in this process in PE pregnancies 
The first 12 weeks of pregnancy are crucial in the establishment of a functioning 
placenta. The two major cascades that have their roots in this timeframe are 
trophoblast differentiation and spiral artery remodeling. Trophoblast differentiation 
begins around 8 weeks of gestation with the cytotrophoblast differentiating into 
syncytiotrophoblast cells (which form a barrier between fetal and maternal blood), and 
the more invasive extravillous trophoblast cells.  The latter cell type, influenced by a 
host of placental and maternal factors such as cytokines, is involved in invading and 
penetrating deep into the maternal decidua. Extravillous trophoblasts differentiate 
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further into endovascular trophoblasts and invade the maternal spiral arteries. These 
cells penetrate and interdigitate the smooth muscle walls of the arteries, and induce 
apoptosis of these cell types. Now spiral arteries are large and flaccid, maximizing 
blood flow to the fetus. 
Both the processes of trophoblast differentiation and spiral artery remodeling are 
known to be deficient in PE pregnancies (Figure1.1).  Increased villous and 
extravillous trophoblast apoptosis is observed in PE pregnancies. This is known to 
occur early in pregnancy and may limit interstitial and endovascular invasion by 
extravillous trophoblasts2. Alternatively, some placental defects may come from poor 
trophoblast differentiation from cytotrophoblast to extravillous trophoblast, leading to 
a smaller population of invasive trophoblasts to migrate to spiral arteries5, 11.  During 
normal pregnancy these spiral arteries are converted from low capacitance, high 
resistance vessels to high capacitance, low resistance vessels. In PE pregnancies, this 
conversion does not occur (Figure1.1). 
What makes this such a complicated disease to study is that the pathological 
cascade is known to begin in Stage 1, but this stage is largely asymptomatic, and 
therefore difficult to examine as clinicians don‟t know which women are destined to 
have pregnancies complicated with PE. Though the use of placental specimens is 
limited to term deliveries, the common characteristics of shallow invasion and reduced 
spiral artery remodeling have provided researchers with an insight into the placental 
pathology underlying the PE disease process.  
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Figure 1.1: Schematic representation of spiral artery remodeling in normal 
pregnancies and pregnancies with PE. The upper panel illustrates the processes of 
trophoblast invasion, remodeling of the spiral arteries, and increased blood flow 
characteristic of normal pregnancy.  The lower panel depicts the defects in these 
process in pregnancies complicated with PE.24 
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 The “holy grail” of PE research is in determining the link between the 
placental defects and challenges that occur in the asymptomatic Stage 1, and the 
maternal syndrome of Stage 2.  This would not only give us a mechanistic idea to the 
etiology of the disease, but provide potential venues for therapeutic intervention.  It is 
accepted that the placenta secretes one or many factors that induce the endothelial 
dysfunction, global inflammation, hypertension and kidney dysfunction characteristic 
of Stage 2 of the syndrome.  Some theories of this placental derived factor(s) include:  
antiangiogenic factors25, syncytiotrophoblast knots and microparticles26, 
autoantibodies to the angiotenisin 1 receptor27, global oxidative stress and an excess of 
reactive oxygen species28, the release of inflammatory cytokines29, 30, and dysregulation 
of nitric oxide pathways12, 31. What has limited researchers to date is that no one factor 
is present in all PE pregnancies, highlighting the heterogeneity of this disorder5, 32.    
1.2.2 Angiogenesis and Oxidative Stress 
A period of hypoxia in early pregnancy is necessary for trophoblast 
differentiation, invasion and proliferation.  These actions are largely mediated by 
redox sensitive transcription factors such as hypoxia inducible factor HIF-1α33.  Up 
until 10-12 weeks gestation, placental development occurs in a hypoxic state. At 10-12 
weeks, trophoblast plugs that have been occluding maternal vessels into the placenta 
are removed and oxygenated blood begins to flow in the placental bed.  One can 
imagine such a profound change in the physiological environment to be a point where 
serious damage could also occur.  Prolonged exposure to hypoxia in vitro using 
placental explants has been shown to lead to increased apoptosis, oxidative stress, 
shedding of syncytiotrophoblast knots, and increased expression several anti-
angiogenic factors, all of which have been shown to be key players in the pathogenesis 
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of PE34, 35.  As such, prolonged oxidative stress has been a promising candidate for the 
link between the two stages of PE. 
 Recently, it has been found that cytotrophoblast cells as well as vascular 
endothelial cells are an important source of NADPH oxidases.  Increased NADPH 
oxidase subunits were found in trophoblast and vascular smooth muscle tissue from 
women with PE implicating oxidative stress in the pathogenesis of the disease28. 
 When placental explants were subjected to hypoxic conditions, one of the 
compounds secreted from the tissue was sFLT-1, a potent anti-angiogenic factor34. 
This finding strongly ties the oxidative stress pathogenesis to the processes of 
angiogenesis and vasculogenesis.  During early placental development, angiogenesis 
and vasculogenesis are some of the major mechanisms that determine placental 
efficiency.  Angiogenic factors from the vascular endothelial growth factor family 
(VEGF) including VEGF-A and closely associated placental growth factor, PGF, are 
extremely important during this timeframe.   VEGF is expressed in uterine natural 
killer cells and trophoblast cells36 and is thought to aid in vascular permeability, 
whereas PGFs role is less well understood.  Both VEGF and PGF share a common 
receptor, FLT-1.  What has become striking in the PE field is the finding that some 
women that show high levels of the soluble form of this receptor, sFLT-1, early in 
gestation are at a greater risk of developing PE25, which launched angiogenic/anti-
angiogenic factors on to a list of potential biomarkers of PE.  
 Soon after the discovery of sFLT-1, an additional soluble antiangiogenic 
factor, soluble endoglin (sENG), was reportedly found in women with severe PE37. 
Endoglin is a part of the transforming growth factor β (TGF-β) receptor complex. 
Analogous to sFLT-1: VEGF/PGF, sENG binds TGF-β and impairs its binding to cell 
surface receptors, and thus promoting an antiangiogenic state.  The use of biomarkers 
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chosen from within the angiogenesis cascade has received a lot of attention in the past 
few decades, though its diagnostic reliability remains controversial.  
1.2.3 The Role of the Inflammatory Response 
An alternative theory puts the immune system as the major player in the 
disease progression. Sargent and colleagues proposed an immunological hypothesis of 
Stage I suggesting that poor invasion of trophoblasts, as a result of inadequate 
expression of human leukocyte antigen isoform G (HLA-G), leads to diminished 
decidual natural killer cell activation leading to decrease in cytokine and angiogenic 
factor production38. This is followed by Stage 2 manifested as a systemic 
inflammatory response involving leukocytes and the endothelial cell activation38. 
 A successful pregnancy relies on specialized control of the maternal immune 
system.  The implantation of the early embryo into the maternal uterine tissue requires 
significant attenuation of the normal „non-self‟ response39. As half of the implanting 
fetus is paternally derived, the embryo and placenta represent a “semi-allograft”11.  
The correct modulation of the immune system requires specific events from both the 
uterus and embryo. The embryo‟s outer cells, the trophoblast, lack MHC class I and II 
expression, which helps the implant evade maternal immune attack11, 40. Trophoblasts 
also express HLA-G, and the uterine decidual tissue expresses Fas ligand, both known 
to promote feto-maternal tolerance41.    
 One of the main mediators of immunotolerance, and a cell type that is gaining 
attention for its role in early placentation is a specialized group of leukocytes known 
as the uterine or decidual natural killer (NK) cells. These cells are unique compared to 
other NK cells and show high CD56 staining2.  Uterine NK cells are present at the 
fetal-maternal milieu in great number, comprising 70% of the leukocyte population in 
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the decidua during early gestation42.  The mechanism of immune evasion involves the 
HLA-G antigen expressed on trophoblast cells binding to NK cells and inhibiting their 
ability to induce cell lysis11.  Probably the two most important roles of these cells are 
in a) trophoblast invasion and spiral artery remodeling (by secreting trophoblast 
invasion promoting cytokines such as interleukin 8 (IL-8) and interferon inducible 
protein 10), and b) promoting immunotolerance to the growing fetus and placenta2, 43.  
Uterine NK cells are also an important source of angiogenic factors PGF, VEGF and 
angiopoeitin-2, which also aid in the early vascularization of the placenta 36. 
 Another important cell type present in large amounts in early pregnancy is 
macrophages.  This cell type occupies 20-25% of decidual leukocytes 44. As cell 
cycling is crucial in early remodeling of the uterine tissue, macrophages are important 
in clearing cellular debris, as well as inducing apoptosis in unwanted cells.  This 
promotes the invasion and growth of extraembryonic tissue 2.   Macrophages are also 
key mediators of angiogenesis due to their secretion of factors including VEGF, 
matrix metalloproteases (MMPs), TGF-β, and fibroblast growth factor45.  Though 
helpful in events of early placentation, excessive activation of macrophages can result 
in significant secretion of pro-inflammatory cytokines.  Macrophages are aberrantly 
activated in PE pregnancies and have roles in inhibiting trophoblast invasion46. The 
significant population of immune cells at the maternal-fetal milieu, and the balance of 
pro- and anti-inflammatory cytokines that mediate many of the early placentation 
processes closely tie the immune system with the success of a pregnancy 47.  Among 
the many potential cell types involved, macrophages and NK cells have received 
significant attention due to their potential role in the early placentation defects seen in 
PE pregnancies. 
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1.2.4 Shallow Invasion and Poor Placental Perfusion 
 An in vivo real-time assessment of shallow invasion leading to poor spiral 
artery remodeling, comes through the use of Doppler ultrasound. As this method is 
already routine in assessing fetal health in the developed world, an additional 
measurement, the resistance in the uterine arteries, is relatively easy to add to the 
standard pregnancy assessment.   Analysis of the uterine artery Doppler, paying 
special attention to “diastolic notches” is becoming routine in sonographic 
examination.  Diastolic notches are where the blood into the placenta shows increased 
resistance, resulting in the appearance of a notch during the beginning of diastole.  
This gives an idea of the degree of placental perfusion.   It is the presence of these 
diastolic notches and increased resistance in uterine arteries early in gestation that has 
been shown to have a strong predictive value in determining which pregnancies will 
be complicated with PE48.  However, similar results of Doppler analysis are predictive 
of IUGR, which shares many of the same placental abnormalities, diminishing the 
utility of this procedure to accurately predict early onset PE5.  This diagnostic tool also 
shows some degree of variability49, and hence is recommended to be used with other 
predictive values such as angiogenic/anti-angiogenic factors50. 
1.2.5  Fetal Stress and Trophoblast Shedding 
A disease of pregnancy has potentially life threatening effects on both the mother 
and the fetus. As such, PE is one of the leading causes of fetal and maternal mortality 
worldwide. Though a lot of attention is paid to the care of the mother throughout 
pregnancy and the health of the unborn child, investigators are now beginning to 
examine the long term effects of the children born to PE pregnancies.  The Barker 
hypothesis states that there are fetal origins of adult diseases, and that stress in utero 
can have lifelong effects 51. In response to poor placental perfusion, the fetus can 
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develop compensatory strategies to overcome the challenged uterine environment. 
These endocrine and metabolic changes can persist well after birth and predispose 
infants born to PE pregnancies to cardiovascular disease later in life52. In fact, 
adolescents born to PE pregnancies have sustained hypertension compared to peers 
born in normal pregnancies53, 54. 
It has long been speculated that a factor secreted from the placenta is the link 
between placental dysfunction and eliciting the global maternal syndrome of PE (see 
above, Two-Stage Hypothesis).  Some of the more promising candidates include 
syncytiotrophoblast microparticles and syncytiotrophoblast “knots”11.  The 
cytotrophoblast cells can differentiate into syncytiotrophoblast layer or extravillous 
trophoblast cells. The syncytiotrophoblast layer is a continuous multinuclear cell layer 
that is the main barrier between fetal and maternal blood. As it is such a vital cell type, 
this layer is under constant turnover during pregnancy. As more new trophoblast cells 
repopulate the syncytiotrophoblast layer, older cells are sloughed off into the maternal 
circulation55, 56.  Normally, the release of these multinucleated knots is initiated by 
apoptotic pathways55, and the dead cells are phagocytosed without initiating an 
immune response.  This is a normal pregnancy occurrence. The difference between 
this normal phenomenon and the pre-eclamptic process is two-fold. There is an 
increased shedding of syncytiotrophoblast knots and microparticles during pre-
eclamptic pregnancies, potentially overwhelming the maternal immune cells, and the 
process of this shedding is not initiated by apoptotic pathways, but via necrotic 
pathways57, 58. When phagocytes engulf these products of necrosis, these cells secrete 
pro-inflammatory cytokines such as interleukin-6, the maternal immune response is 
heightened, and endothelial dysfunction progresses58. 
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In summary, a significant amount of evidence indicates that there is undoubtedly a 
role for oxidative stress, angiogenic imbalance, the immune system, poor placental 
perfusion and the secretion of placental debris in the development of PE. However, the 
links between and among these hypotheses are not understood. 
 
1.3  Before Placentation: the Potential Role of Implantation in PE 
As the field of PE research has expanded in the past few decades, researchers are 
largely focused on the placenta as the causative factor in the pathophysiology of the 
disease. Our focus to date has been on placental defects and serum markers that are 
present in the maternal circulation after 12 weeks, when blood is flowing into the 
placenta. Huppertz, however, argues that some potential serum markers used to predict 
PE happen as early as 7 weeks, and hint towards an even earlier frame of 
investigation5.  Huppertz challenged the way we think of PE by tracing its origins to 
the time of implantation. Indeed, implantation itself sets the cascade for placentation, 
therefore it stands to reason that defects at the time of implantation could result in poor 
placental outcomes.  Huppertz proposes the origin of PE at the stage of trophoblast 
differentiation, which is in the pre-implantation period, prior to embryo invasion into 
the uterine wall5.  Futhermore, he suggests that the difference in placental pathology 
between PE and IUGR phenotypes can be traced to the process of differentiation of 
villous and extravillous trophoblast, which again puts the focus of the initiation of the 
pathological cascade far upstream of what was previously considered5.   Subsets of 
pregnancies that are at particularly high risk of developing PE are those associated 
with assisted reproductive technologies.  Specifically, pregnancies initiated by in vitro 
fertilization (IVF) are at an increased risk for the development of PE59.  In part this is 
due to the increase of multiple offspring as a result of this procedure60.  Pregnancies 
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with multiple offspring are at a higher incidence of development of PE.  However one 
important statistic is that singleton pregnancies initiated by IVF have a significantly 
increased risk of developing PE, ruling out the multiparous risk factor60. One of the 
features that sets these pregnancies apart from natural pregnancies is that processes up 
to and including the time of implantation are artificially induced.  The process of 
implantation is not completely understood.  With a success rate of merely 30%, this 
highlights a deficit in our understanding of this process.   With the high incidence of 
PE in IVF pregnancies, it supports the shift of focus that we currently have on 
placentation, back to the period of implantation. 
1.4 Rodents As Models of Human Pregnancy 
As previously stated, studying a disease so closely associated with placentation, as 
is the case for PE, leads to difficulties in studying this disease in the context of the 
human condition. Therefore, researchers have turned to animal models, mostly rodent 
models, for a number of reasons. The rodent embryo, particularly the murine embryo, 
invades into the maternal uterine wall and induces a decidual response, much like the 
progression of human pregnancy and implantation.  The placental architecture of mice 
and humans are remarkably similar with analogous structures of the chorionic villi in 
humans to the highly branched labyrinth in mice, and the outer extravillous 
cytotrophoblast in humans compared to the trophoblast giant cells in mice61.  Murine 
placentae show hemochorial blood flow, much like the human placental interface 61.  
As in humans, mouse trophoblast cells are involved in invading and remodeling spiral 
arteries, a key process in the modeling of the early stages of PE. These analogous cell 
types not only share functional properties with the human counterparts, but their 
genetic profile also shows marked similarities, allowing researchers to more 
thoroughly examine unique genetic contributions to placentation62. 
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 With the ease of a short reproductive term (roughly 20 days) come some 
limitations to studying murine pregnancy as a model of human pregnancy. The most 
obvious is the fact that mice are a litter bearing species, where the health of each 
implantation site could potentially affect the pregnancy as a whole.   The profile of a 
pregnancy where many implantation sites are resorbed, versus a perfect pregnancy 
with 7-10 healthy conceptuses could be very different on a physiological and 
molecular scale.  Many aspects of spacing and competition among implantation sites is 
seldom analogous to human pregnancies, where multiple pregnancies conceived 
naturally are relatively rare. 
 Where timing is advantageous and convenient in studying murine pregnancies, 
it can also be a disadvantage. In processes taking several months in a human 
pregnancy, researchers have only a few days to track such events in rodent models.  
This poses a unique challenge for researchers to track analgous potential deleterious 
events that may lead to the development of diseases such as PE. 
 A particular area which has seen great technological advancement in rodent 
pregnancies is in the area of imaging.  Tools such as ultrasound and microCT imaging 
have allowed in vivo physiological data to be acquired on murine embryos where 
previous restrictions on resolution made these assessments impossible. Doppler 
ultrasound has enabled researchers to examine fetal heart rates and umbilical and 
placental blood flow in developing mouse embryos from very early embryonic 
stages63, 64. Murine pregnancies can model many of the characteristics of human PE 
including increased uterine artery Doppler resistance indices of poor placentation65, 66.  
Where ultrasound has given us a new tool to examine embryonic health and placental 
function in utero, microCT has seen improvement in resolution as well which allows 
the detection of vasculature down to 25μm, a scale now appropriate for murine 
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placental vasculature.  This improved technique now allows for the qualitative and 
quantitative assessment of numerous vascular defects, including those found in 
placentation. This opens the door for more detailed phenotyping of genetically 
engineered mice67, 68.  
1.5 Rodent Models of Pre-eclampsia: Clues and Limitations 
1.5.1 The rat model of placental ischemia: 
One of the potential outcomes of the lack of spiral artery remodeling in PE 
placentae is global placental ischemia.   A relatively popular rodent model of PE relies 
on this pathological feature as a basis of exploring how reduced placental perfusion 
may lead to the development of PE-like symptoms.  This rat model, termed the 
Reduced Uterine Perfusion Pressure (or RUPP) model, is where Sprague-Dawley rats 
receive a uterine artery clip on day 14 of pregnancy around the aorta below the renal 
arteries, and to inhibit the compensatory increase in uterine flow via branches of the 
ovarian artery, clips are placed there as well69.  This decreases uterine blood flow up to 
40%69.  Shortly after the clip is placed, rats exhibit an increase in maternal blood 
pressure and reduced kidney function70. Pups from this model are small, showing that 
despite how late in the pregnancy the clips are inserted, the restriction is still enough 
to elicit IUGR in this model 70.  RUPP animals also exhibit increased response to 
vasoactive substances, impaired vascular relaxation and global endothelial 
dysfunction71.  In the angiogenic profile arena, the RUPP animals show increased 
sFLT1 and sENG production, and which results in reduced circulating VEGF  
levels70, 72. Interestingly, when VEGF is given to supplement the deficient circulating 
levels of this important angiogenic factor, the PE symptomology is largely resolved70. 
 The drawback of the RUPP model is simple. In its design, RUPP only 
considers the response to placental ischemia as the founding basis of the development 
18 
 
of PE, where it is commonly accepted that the etiology of PE is probably from several 
early pathological events, including but not limited to poor placental perfusion.  
Additionally, as the RUPP model is surgically induced, animals show no endogenous 
placental abnormalities that illustrate what is seen in human samples. Implementing 
the arterial clips under anesthesia at mid-gestation, and also recording from these rats 
post-clipping requires significant handling stress, both of which likely confound the 
model significantly.  
1.5.2 The sFLT-1 infusion model 
A seminal study by Maynard and colleagues put the sFLT1 infusion model as 
another important model of PE in the field. By increasing systemic levels of this anti-
angiogenic factor, pregnant rats showed increases in blood pressure and proteinuria, 
and glomerular endotheliosis that resembled PE pathology25.  This intervention study 
also correlated with samples from women with PE that exhibited increased sFLT-1 
levels and decreased PGF levels73.   
 The drawbacks of this model are similar to those of the RUPP model in 
providing a narrow mechanistic view in the development of PE symptoms.  
Importantly, this model probably administers sFLT1 levels far surpassing 
physiological conditions.  Physiologically, the placenta is an important source of 
sFLT1, and is completely bypassed in this model with exogenous sFLT1 
administration.   Additionally, it has been shown by several groups that sFLT1 is not a 
causative link to PE, as many women do not show an increase in sFLT1 and go on to 
develop PE while others show normal sFLT1 and develop the syndrome74, 75.   
1.5.3 Renin-angiotensin Transgenic Rat Model 
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The role of the renin angiotensin system (RAS) has also been strongly 
implicated in the hypertensive phenotype of the PE syndrome. During a normal 
pregnancy, women show increased renin and AngII in the plasma, yet show a decrease 
in vascular responsiveness to AngII, leading to the maintenance of basal blood 
pressure76. Women with PE, however, tend to have increased responsiveness to AngII 
despite significantly lower circulating AngII levels77. What has become important in 
considering the role of RAS has been the separation of global systemic activation with 
local utero-placental RAS signaling77, 78.  To elucidate the role of the 
fetoplacental/uteroplacental RAS pathway, a specific rodent model is used in which a 
dam carrying a transgene for human angiotensinogen (hAogen) is mated with a sire 
carrying the human transgene for human renin (hRen), which results in a PE like 
syndrome during the second half of pregnancy, where hypertension and proteinuria are 
observed79, 80. Recent work by Dechend and colleagues have examined the question of 
local RAS (using the rat RAS PE model), the opposite cross, and elevating systemic 
AngII with osmotic mini-pumps in the development of these symptoms.  The blood 
pressure and proteinuria phenotypes were only shown in the PE model and AngII 
infusion model suggesting that the increased circulating AngII is the common link 
among all of these phenotypes 78. Surprisingly, the opposite cross (dam with hRen x 
sire with hAogen) would have only local uteroplacental increases in AngII showed 
increased trophoblast invasion and spiral artery remodeling.  This suggests that 
uteroplacental AngII and not circulating AngII is important for these placental 
processes78. Uteroplacental blood flow as measured by ultrasound showed a lower 
resistance index for the opposite cross and the PE model, reflecting the improved 
invasion and remodeling. 
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 The limitations of this model are in its placental pathology. It is commonly 
accepted that a lack of spiral artery remodeling is a common and important feature of 
pre-eclamptic placentae. This lack of spiral artery remodeling is linked to increased 
vascular resistance as seen in Doppler ultrasound, and perhaps linked to increased 
trophoblast shedding and placental debris (see above). If anything, this PE rat model 
actually shows improved and deeper invasion and remodeling of spiral arteries, 
followed by improved resistance indices as measured by ultrasound 78, 79, 81.  This 
model goes against accepted theory linking the deficiency in vessel remodeling to the 
development of the hallmarks of the disease, showing an increased BP and proteinuria 
in the presence of improved spiral artery remodeling.  
1.5.4 Auto-antibody infusion model 
Given the complications with the transgenic rat model of PE (described above) 
the RAS field has seen an important and promising new target to examine in the 
development of PE symptomology.  In 1999, Wallukat et al. found that patients with 
pre-eclampsia exhibited increased circulating levels of autoantibodies against the 
angiotensin 1 receptor (AT1-AA)27. The hypothesis is that these antibodies bind to the 
AT1 receptor in an agonist fashion and activate the AT1 receptor leading to the 
increased AngII responsiveness in PE women24, 27.  Since this finding, PE symptoms 
have been recapitulated in mice via an injection of autoantibodies isolated from 
women with PE, injected into mice mid-gestation82. With this AT1-AA model, mice 
exhibit increased blood pressure and proteinuria as well as glomerular lesions82. In this 
model, all of these phenotypes can be blocked by either losartan treatment (an AT1 
receptor antagonist), or antibodies against the 7 amino acids used in antibody-receptor 
binding82.  Interestingly, other rodent models have looked for autoantibodies, and 
AT1-AAs are present in the RUPP model, the transgenic RAS PE model as well as a 
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model in which low levels of tumor necrosis factor alpha (TNFα) are infused into 
pregnant rats83, 84.   More recently, groups have considered the role of TNFα and AT1-
AA induced PE symptomology.  It is clear that the important cytokine TNFα plays a 
role in this model of PE85, 86.  An interesting parallel also lies in the link between AT1-
AA and TNFα induction and the increase in circulating anti-angiogenic factors sFLT1 
and sENG, arguing for a role of the inflammatory response in the production of these 
potent anti-angiogenic factors86. 
 The limitation of this new model is that the cascade leading to the source of 
these autoantibodies is largely unknown. Again the role of the placenta in this cascade 
is unclear in how placental ischemia plays a role in the development of this auto-
immune condition.  In vitro work has shown that AT1-AA can activate vascular cells 
and trophoblast, and induce reactive oxygen species via the activation of NADPH 
oxidase87.  The full cascade of this auto-immune response warrants further study.  
1.6 The BPH/5 model of Pre-elampsia 
1.6.1 Hallmarks of PE 
Part of the limitations of numerous rodent models of PE is that they require 
surgical, pharmacological or genetic manipulation. Though they help to elucidate 
potential mechanisms that may underlie the pathology, they do so with a narrow frame 
of reference.  Many of the means to induce PE symptoms are fairly invasive which 
makes deciphering the cause and effect difficult. 
BPH/5 is an inbred mouse model that spontaneously exhibits symptoms of PE 
during pregnancy66.   This strain was derived by Schlager and colleagues from the well 
established hypertensive mouse strain BPH/288, 89.  In the non-pregnant state, BPH/5 
show a mildly elevated basal blood pressure, a known risk factor for the development 
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of PE in humans17.  During pregnancy, this hypertension profile increases significantly 
beginning late in gestation (starting at d14.5), results in frank hypertension, and 
resolves upon delivery of the litter66.  Additionally, pregnant BPH/5 show increased 
proteinuria late in gestation which also resolves upon delivery of the pups. These 
hallmarks of PE mirror the timing of a human pre-eclamptic pregnancy with the onset 
of symptoms at the beginning of the third trimester.  Additionally, significant 
glomerulosclerosis and endothelial dysfunction are exhibited in late gestation in this 
mouse model66, which are also found in women with PE. 
1.6.2     Placental Defects in BPH/5 Mimic Human Placental Samples 
As discussed previously (section 1.1.3), significant placental pathology is 
associated with PE.  The telltale reduced spiral artery remodeling and shallow 
trophoblast invasion into the decidua is also found in BPH/5 90. Additionally, the 
labyrithe area is severely underdeveloped showing reduced means of nutrient/oxygen 
exchange.  Due to elevated resistance in the placental vascular bed, uterine artery 
Doppler late in gestation show increased resistance in the uterine vessels90.  Taken 
together, the BPH/5 placental structure is severely compromised, and bears a strong 
resemblance to defects found in human PE placentae. 
1.6.3 Oxidative stress  
An additional correlation between human pregnancies and BPH/5 placental 
samples is evidence of oxidative stress. Prolonged hypoxia, coupled with increased 
production of reactive oxygen species (ROS) and deficient antioxidant capacity is 
thought to contribute to oxidative stress characteristic of PE pregnancies 91-93.  As 
shown by Hoffmann and colleagues, BPH/5 placentae show increased ROS levels and 
decreased antioxidant capacity compared to control strains 94. Additionally, chronic 
treatment with an SOD mimetic Tempol dramatically reduced ROS levels in the 
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placenta as well as significantly diminishing the late gestational hypertension and 
proteinuria characteristic of BPH/5 pregnancies.  These studies support a strong 
rationale for antioxidant enrichment in pregnancies complicated with PE. 
1.7 Statement of the Problem 
Pre-eclampsia is a serious disease of pregnancy that has seen limited progress in its 
understanding and treatment. Our lab discovered a mouse model that spontaneously 
exhibits the symptoms of PE including late gestational hypertension, proteinuria and 
placental pathology reminiscent of the human condition. This mouse model provides 
an important tool to examine specific questions in the pathology of the PE. 
Initially, we began by examining the angiogenic potential in this mouse model as 
angiogenesis and angiogenic factors have seen increased research in recent years for 
their potential biomarker capability.  One of the benefits of such an animal model in 
which the disease occurs spontaneously is that we can examine early pre-maternal 
syndrome timepoints that are unavailable for study in the human case and also in 
many of the other animal models.  BPH/5 show signs of fetal stress early in gestation, 
and we sought to characterize this timepoint via microarray analysis to examine the 
molecular profile of healthy and challenged embryos. Finally, as the field focuses 
earlier and earlier on the pregnancy timeline in the initiation of the pathology cascade, 
we examined the peri-implantation period in BPH/5 mice.  The goal of this research is 
to use the results from each of these separate studies to create a unifying hypothesis 
and working model to examine the causes of PE in BPH/5.  
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Figure 1.2: Schematic representation of a the BPH/5 pregnancy and the relevant 
timepoints that will be examined in the subsequent thesis chapters.  
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1.8 Approach 
In order to test the hypothesis that there is an angiogenic defect in BPH/5 mice we 
employed protein and molecular assays at different gestational stages to track the 
angiogenic potential of BPH/5 mice. Additionally, we intervened using viral mediated 
gene transfer of an important angiogenic factor to determine if this factor was 
functionally linked to maternal and fetoplacental PE outcomes in vivo.  
 To test the hypothesis that there is a distinct molecular profile present in 
BPH/5 fetoplacental units early in pregnancy compared to controls, we used cutting-
edge high resolution ultrasound to assess the fetal health status of BPH/5 embryos, 
followed by microarray analysis of these fetoplacental units. 
 Finally, to test the hypothesis that PE has its roots in the peri-implantation 
period, BPH/5 embryos were examined for their pre-implantation potential, and how 
those defects translate into implantation defects. Surgical reciprocal embryo transfers 
as well as ovariectomies with hormone supplementation were used to fully 
characterize the fetal and maternal components to implantation defects.  Ultimately, 
the role of implantation in the placental pathology observed in BPH/5 was examined. 
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CHAPTER TWO: 
ADENOVIRAL DELIVERY OF VEGF121 EARLY IN PREGNANCY 
PREVENTS SPONTANEOUS DEVELOPMENT OF PRE-ECLAMPSIA IN 
BPH/5 MICE* 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Most  of the work in this chapter is published in Woods, A.K., Hoffmann, D.S, 
Weydert, C.J., Butler, S.D., Zhou, Y., Sharma, R.V., Davisson, R.L. Hypertension (in 
press) 
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SUMMARY 
 
An imbalance in circulating pro-angiogenic and anti-angiogenic factors is postulated 
to play a causal role in pre-eclampsia (PE). We have described an inbred mouse strain, 
BPH/5, which spontaneously develops a PE-like syndrome including late-gestational 
hypertension, proteinuria, and poor fetoplacental outcomes. Here we tested the 
hypothesis that an angiogenic imbalance during pregnancy in BPH/5 mice leads to the 
development of PE-like phenotypes in this model. Similar to clinical findings, plasma 
from pregnant BPH/5 showed reduced levels of free vascular endothelial growth factor 
(VEGF) and placental growth factor (PGF) compared to C57BL/6 controls. This was 
paralleled by a marked decrease in VEGF protein and Pgf mRNA in BPH/5 placentae. 
Surprisingly, antagonism by the soluble form of the FLT1 receptor (sFLT1) did not 
appear to be the cause of this reduction, as sFLT1 levels were unchanged or even 
reduced in BPH/5 compared to controls. Adenoviral-mediated delivery of VEGF121 
(Ad-VEGF) via tail vein at e7.5 normalized both the plasma free VEGF levels in 
BPH/5 and restored the in vitro angiogenic capacity of serum from these mice. Ad-
VEGF also reduced the incidence of fetal resorptions and prevented the late-
gestational spike in blood pressure and proteinuria observed in BPH/5. These data 
underscore the importance of dysregulation of angiogenic factors in the pathogenesis 
of PE, and suggest the potential utility of early pro-angiogenic therapies in treating 
this disease.
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INTRODUCTION 
Pre-eclampsia (PE) is a pregnancy-specific syndrome defined by sudden onset 
of hypertension and proteinuria after 20 weeks gestation. A multi-system disorder that 
impacts both mother and fetus, PE is a major public health problem. Worldwide, PE 
affects 5-8% of pregnancies and is the leading cause of maternal and fetal deaths
1, 2
. In 
developing countries, the incidence of PE is even higher
3
. Despite its common 
occurrence and serious consequences, treatment of PE has not changed over the last 
century. Even today, the only known effective means to avoid progression to 
eclampsia is delivery of the fetus and placenta. As such, PE accounts for up to 20% of 
preterm births worldwide
3
.  
         The etiology of PE remains unclear, however there is growing evidence that an 
imbalance in several members of the vascular endothelial growth factor (VEGF) 
family and its receptors is linked to the clinical syndrome
1, 4
. VEGF-A (VEGF), 
critical to angiogenesis and vasculogenesis required for placentation, is present in 
numerous isoforms
5
. VEGF121, the predominant isoform, lacks a membrane-bound 
motif, making it freely diffusible and therefore having the greatest therapeutic 
potential
5
. The closely related placental growth factor (PGF) shares 42% sequence 
homology to VEGF and shares a common receptor, VEGFR-1 (i.e. Fms-like tyrosine 
kinase 1, FLT1)
6, 7
.  Many women who develop PE show decreases in circulating free 
VEGF and PGF starting in early- to mid-gestation
1, 2, 8
.  In addition, high levels of the 
soluble form of the FLT1 receptor (sFLT1) and soluble endoglin (sENG), both anti-
angiogenic factors, are also reported in PE patients at various times during pregnancy
9-
11
. On the other hand, increased serum sFLT1 levels are not always observed in 
women with PE
12
, and a recent study showed that not only were elevated sFLT1 levels 
at 11-14 weeks not predictive of PE in women, but were in fact associated with 
reduced risk for delivery of a small-for-gestational-age baby
13
.       
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           Despite discrepancies in clinical findings, significant progress in basic research 
has been made to support the hypothesis that an imbalance between pro-angiogenic 
and anti-angiogenic factors is involved in the pathogenesis of PE. Maynard et al. 
found that adenoviral-mediated increases in circulating sFLT1 levels in normal 
pregnant rats induced a PE-like syndrome
9
.  A similar study in mice confirmed that 
exogenous delivery of sFLT1 during pregnancy can induce late-gestational 
hypertension
14
. To determine if the effects of exogenous sFLT1 could be 
counterbalanced by increasing pro-angiogenic factors, Li et al. used repeated 
subcutaneous injections of VEGF121 and found that this attenuated PE symptoms in 
pregnant rats previously made pre-eclamptic by an adenovirus encoding sFLT1
15
. A 
similar strategy was adopted by Gilbert et al. in the context of a rat model in which the 
uteroplacental circulation is disrupted at mid-gestation, and increased circulating 
levels of sFLT1 late in pregnancy were observed
16
. These studies provide important 
proof-of-concept that an angiogenic imbalance can induce some aspects of PE, 
however the experimental design is somewhat predictive of the outcome. Testing 
whether there is endogenous angiogenic imbalance in an animal model that 
spontaneously develops PE is an important next step. 
             Several years ago we described an inbred murine strain, BPH/5, which 
spontaneously develops a maternal and fetoplacental syndrome that bears striking 
resemblance to PE
17
. The model is characterized by late-gestational hypertension, 
proteinuria, renal glomerular lesions and endothelial dysfunction
17, 18
. In addition to 
the maternal systemic disorder, BPH/5 also show fetoplacental defects reminiscent of 
human PE, including defective trophoblast invasion of the maternal decidua and 
diminished remodeling of maternal spiral arteries
19
. This translates into dramatic 
decreases in end-diastolic blood flow in uterine arteries
19
, taken clinically to indicate 
placental vascular insufficiency
20
. BPH/5 also exhibit impaired endothelial cell 
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branching and development of the fetal labyrinth, which is associated with fetal 
growth restriction, intrauterine fetal demise and small litters of low birth-weight 
pups
17-19
.  
           Based on our findings of fetoplacental defects indicative of poor 
angiogenesis/vasculogenesis in the BPH/5 model, together with clinical evidence of an 
angiogenic imbalance in women with PE, we hypothesized that BPH/5 would exhibit 
altered levels of endogenous pro- and anti-angiogenic factors during pregnancy, and 
this would translate into a maternal and fetoplacental syndrome that resembles human 
PE. Here we demonstrate that an angiogenic imbalance is present in BPH/5 mice 
during early-to-mid gestation, and this is due to decreased levels of pro-angiogenic 
VEGF and PGF, but not increased levels of anti-angiogenic sFLT1. Adenovirus-
mediated delivery of VEGF121 early in pregnancy (e7.5) in BPH/5 normalized VEGF 
levels, reduced fetal resorptions and prevented spontaneous development of late-
gestational hypertension and proteinuria in this model. These data underscore the 
importance of angiogenic imbalance in the pathogenesis of PE, and further suggest the 
potential utility of early pro-angiogenic therapies in treating this disease. 
 
METHODS 
Animals and Husbandry.  Experiments were performed in 8-12 wk old BPH/5 and 
control C57Bl/6 (C57) mice obtained from in-house colonies. Animals were housed 
and maintained as previously described
17
. BPH/5 is an inbred strain derived from the 
spontaneously hypertensive BPH/2 strain, which was originally established through an 
eight-way cross that included C57Bl/6
17, 21
. Mice underwent strain-matched mating 
and presence of a vaginal plug in the morning was defined as gestational day e0.5
17
. 
Gestational stages were defined as early: e9.5-12.5; middle: e13.5-15.5; and late: 
e18.5-19.5. All animal procedures were approved by the Institutional Animal Care and 
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Use Committees at The University of Iowa and Cornell University, and are in 
accordance with the PHS Guide for the Care and Use of Laboratory Animals, USDA 
regulations and the AUMA panel on Euthanasia. 
 
Adenovirus delivery. Adenoviral vectors encoding VEGF121 (Ad-VEGF) and a control 
gene β-galactosidase (Ad-LacZ) were prepared by the University of Iowa Gene 
Transfer Vector Core as described previously
22
  Briefly, cDNA for VEGFA121 was 
cloned into the E1-deleted region
 
of the replication-deficient E1/E3 deleted Ad5 
adenovirus vector backbone
23
. Expression of the VEGF121 gene in this viral construct 
was driven by the RSV promoter
22
. Virus was double-purified and the titer determined 
as described
22
. Ad-VEGF or Ad-LacZ were injected into C57 and BPH/5 via tail vein 
on e7.5 (100 µl, 10
9
 plaque forming units).   
 
Enzyme-Linked Immunosorbent Assay (ELISA).  To determine circulating levels of 
VEGF, PGF, sFLT1 and sENG, blood was collected from non-pregnant (NP), early, 
and mid-gestation BPH/5 and C57 females via cardiac puncture and fractionated using 
EDTA collection tubes.  Plasma was isolated from blood samples spun within 30 
minutes of collection at 3500 RPM for 15 minutes at 4ºC and immediately frozen at -
80ºC. All ELISA kits were purchased from R&D systems and assays were performed 
according to manufacturer‟s instructions. For measuring free VEGF, plasma was 
diluted 2-fold for NP mice and 5- to 10-fold for pregnant mice using assay diluent. 
The sensitivity for this assay was 3 pg/mL. To determine plasma free levels of PGF, 
ELISA analysis of undiluted plasma samples from NP, early, and mid-gestation were 
performed. The sensitivity for this assay was 2 pg/mL. Circulating levels of sFLT1 
were determined by ELISA on plasma samples diluted 2-fold for NP mice and diluted 
10-fold for pregnant mice.  The sensitivity of this assay was 15 pg/mL. Finally, to 
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measure sENG, ELISA was performed on plasma diluted 5-fold for NP, early- and 
mid-gestation samples. The sensitivity of this assay was 60 pg/mL. 
 
Quantitative real-time PCR. BPH/5 and C57 mouse placentae were collected at e9.5, 
e12.5, e14.5 and e18.5 (sFlt-1 only). Samples contained extraembryonic tissues 
including the decidua basalis and placenta, but excluded the umbilical cord and 
embryo proper. Placentae from each litter were pooled to create one biological sample 
(n=1) and total RNA was isolated utilizing a RNeasy kit according to manufacturer‟s 
instructions (Qiagen). Quality of RNA samples was determined by denaturing agarose 
gel electrophoresis and total RNA content quantified by spectrophotometry. 
Quantitation of Vegf, Pgf and sFlt1 expression levels were performed by amplification 
of  cDNA (equivalent to 10 ng input RNA) using SYBR Green and primers specific to 
each gene (ABI 7700, PE Biosystems).  Primers were selected using a combination of 
Primer Express software (Applied Biosystems) and Primer Bank (Harvard University 
http://pga.mgh.harvard.edu/cgi-bin/primerbank).  All primers were purchased from 
integrated DNA technologies (IDT). The primers used were as follows: Vegf 
(NM_001025250): forward 5‟-CTT GTT CAG AGC GGA GAA AGC-3‟, reverse: 5‟-
ACA TCT GCA AGT ACG TTC GTT-3‟; Pgf ( NM_008827): forward 5‟-TCT GCT 
GGG AAC AAC TCA ACA-3‟, reverse 5‟-GTG AGA CAC CTC ATC AGG GTA T-
3‟; sFlt-1 (D88690): forward 5‟-ACG TGT GTT TCC TGC TGT GT-3‟ and reverse 
5‟- TCA AAG CTT GGT GAA GGG CT-3‟; and beta actin: forward 5'CAT CCT 
CTT CCT CCC TGG AGA AGA 3' and reverse: 5' ACA GGA TTC CAT ACC CAA 
GAA GGA AGG 3'.  Samples were subjected to forty cycles of PCR (50 , 2 min; 95 , 
10 min; 40X [95 , 0:15 min; 60 , 1 min]) followed by a dissociation protocol.  Each 
sample was run in triplicate and gene expression was analyzed using the ddCt method.  
mRNA levels were normalized to β-actin (to generate dCt) and compared to C57 e9.5 
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(to generate ddCt).  Sequence-specific amplification was confirmed by a single peak 
during the dissociation protocol following amplification.  
 
Western blot analysis. Placentae were collected at early and mid-gestation from 
BPH/5 and C57 mice as described above. Samples were weighed, pooled from each 
litter (n=1) and homogenized in 50 mM potassium phosphate buffer (pH 7.8). 
Homogenates were sonicated for 30s at 30% amplitude (Sonics and Materials). Protein 
concentration was determined with the Bradford assay as previously described.
18
 
Equal amounts of protein (30 g protein) were separated on a 12.5% SDS-PAGE gel 
and were transferred to PVDF membrane. Membranes were blocked in 5% dry milk in 
TBST (0.01 mol/L Tris, 0.15mol/L NaCl buffer pH8.0 and 0.1% Tween 20) for 2 
hours.
18
 VEGF levels were measured using an antibody that recognized both VEGF121 
and VEGF165 isoforms (anti-goat VEGF, 1:500, Sigma-Aldrich, St. Louis, MO). Blots 
were incubated  for 1h at room temperature with primary antibody, washed three times 
in TBST, followed by incubation with secondary antibody for an additional hour 
(donkey anti-goat IgG peroxidase  
1:10 000, Santa Cruz). Blots were stripped and re-probed with a monoclonal anti-actin 
antibody (Sigma Aldrich). Densitometry of VEGF and actin blots was performed 
utilizing the BioRad Quantity One. Band intensities were normalized to actin. Values 
were normalized to the early gestation C57 band for each blot.  Experiments were run 
in triplicate. 
 
In Vitro Angiogenesis Assay. The in vitro angiogenesis assay was performed utilizing 
human umbilical vein endothelial cells (HUVEC) using an In Vitro Angiogenesis Kit 
(Trevigen) according to manufacturer‟s instructions. Briefly, black Optilux 96 well 
plates (Falcon) were coated with growth factor reduced matrigel (Trevigen) and were 
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stored for 30 mins at 37
o
C to allow polymerization.  HUVEC cells obtained from 
B&D Biosciences were cultured in 75mm culture flasks according to manufacturer‟s 
instructions. Confluent cells in flasks were incubated with Calcein AM for 30 mins 
and trypsinized. Approximately 25,000 cells were plated in matrigel-coated 96 well 
plates and cultured for 18-20hrs in medium supplemented with either 5% FBS or 
serum collected from different experimental animals.  Plates were imaged using 1.25x 
objective on a Leica DMI 6000B inverted microscope equipped with green fluorescent 
protein imaging filters. Total tube lengths in the entire well were measured by 
experimenters blind to the treatments using Image J software.  Data are normalized to 
the positive FBS control for total tube length. 
 
Radiotelemetric measurement of blood pressure throughout pregnancy.  For 
longitudinal blood pressure measurements, NP female BPH/5 and C57 mice were 
surgically implanted with radiotelemeters as described previously.
24
 Mice were 
allowed to recover fully for 7 days prior to baseline recording and strain-matched 
mating. Arterial blood pressure was recorded for 3 consecutive days prior to mating 
utilizing Dataquest ART data acquisition system (Data Sciences Int). Following strain-
matched breeding and detection of a vaginal plug (e0.5), blood pressure was recorded 
as described previously
17, 18
. Titer-matched Ad-VEGF or Ad-LacZ control vector (100 
µL, 1x10
9
 pfu) was injected via tail vein on e7.5 in both strains and arterial pressure 
recording was continued throughout the duration of pregnancy (~20 days) and for an 
additional week post-partum.  
 
Urine protein analysis. Urine samples were collected from mid- and late-gestation 
C57 and BPH/5 females injected with Ad-VEGF or Ad-LacZ on e7.5 and frozen at -
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20°C until analysis as described
17, 18
. Protein analysis was performed using Bradford 
reagent as described
17, 18
.   
 
Analysis of pregnancy outcomes.  C57 and BPH/5 females treated with Ad-LacZ or 
Ad-VEGF on e7.5 were euthanized at mid-gestation. The uterine horns were exposed, 
and the fetuses were counted. Fetal resorptions were identified by 
necrotic/hemorrhagic appearance compared with normal viable fetuses
17, 18
. In two 
additional cohorts of both strains treated with Ad-LacZ or Ad-VEGF at e7.5, placental 
and fetal weights at e14.5 and e18.5 were recorded for all pups from each litter. 
Finally, the numbers of live pups born were recorded in yet another cohort of BPH/5 
and C57 females treated with Ad-LacZ or Ad-VEGF and allowed to deliver.  
 
Morphometric analysis and Immunohistochemistry. C57 and BPH/5 females that had 
been treated with Ad-LacZ or Ad-VEGF on e7.5 were euthanized at e12.5.  
Fetoplacental units were removed, fixed in 10% neutral buffered formalin, and 
paraffin embedded using standard procedures.  Tissues were sectioned at 5µm, and 
stained with isolectin B4 to stain the basement membrane of endothelial cells in the 
labyrinth and maternal deciduas, and Masson‟s Trichrome stain to stain the vessels in 
the placenta as previously described 
19
. Placental depth, labryrinth area and junctional 
zone area were measured as described in 
19
.  Spiral arteries were imaged and 
quantified by the ratio of the outer lumen diameter (OD) to the lumen diameter (LD), 
measured at the point where the OD was the largest.  
 
Statistical analysis.  Data are expressed as mean ± SEM. ANOVA followed by 
Newman-Keuls test for significance was performed for all data sets. p<0.05 was 
considered statistically significant. 
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RESULTS 
Angiogenic imbalance in pregnant BPH/5 is due to decreased pro-angiogenic 
factors. Free VEGF levels were compared in BPH/5 and C57 plasma from early- and 
mid-gestation. We focused on these time-points since clinical data points to early- or 
mid-gestational decreases in VEGF in women with PE
1, 8
. There was a marked 
increase in circulating free VEGF in C57 controls at both early- and mid-gestation 
compared to NP levels (Figure 2.1A). BPH/5 also showed pregnancy-induced 
increases in plasma VEGF, however this was significantly blunted at both time-points 
compared to C57 (Figure 2.1A). Since the placenta is an important source of 
angiogenic factors during pregnancy
25
, we next compared Vegf mRNA levels in 
placental samples from C57 and BPH/5 at three time-points. Summary data presented 
in Figure 2.1B shows no differences in Vegf transcript levels between C57 and BPH/5 
at any of the gestational time-points examined. Since emerging evidence suggests that 
VEGF expression is regulated via miRNA-mediated repression of Vegf mRNA 
translation
26
, we next measured VEGF protein in placentae using Western analysis. As 
seen in Figure 2.1C and 2.1D, VEGF protein expression was significantly decreased in 
BPH/5 placentae at both early- and mid-gestational time-points compared to C57 
controls, consistent with the plasma VEGF data. 
         We next compared circulating free PGF in BPH/5 and C57 at early- and mid-
gestation since decreased levels of this growth factor at these time-points is associated 
with PE in women.
8
 There was a marked early increase in plasma PGF levels in C57, 
and this returned to NP levels by mid-gestation (Figure 2.2A). Although BPH/5 
showed a significant elevation in free PGF levels at early gestation compared to NP 
levels, this pregnancy-induced PGF increase was significantly reduced compared to 
C57 controls (Figure 2.2A). Since this suggested that BPH/5 placentae produce only 
modest levels of PGF, we next examined Pgf transcript levels in this tissue using real- 
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Figure 2.1: Circulating and placental VEGF levels are decreased in BPH/5. A) 
Summary of circulating free VEGF as determined by ELISA in non-pregnant (NP) 
and at early and mid-gestation C57 and BPH/5 (n=4-6 per group). B) Summary of 
real-time qPCR analysis of placental Vegf mRNA levels at different days of gestation 
(n=5 per group). Data are expressed relative to C57 at e9.5 C) Representative Western 
blot of VEGF protein levels in placenta samples from C57 (C) and BPH/5 (B) at early 
and mid-gestation. β-actin served as loading control. D) Summary of Western blot 
quantification (n=3 per group at each time-point) normalized to actin and expressed 
relative to C57 early. *p<0.05 vs NP in matched strain; †p<0.05 vs. time-matched 
C57. 
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Figure 2.2: Pro-angiogenic PGF is downregulated, whereas anti-angiogenic 
sFLT1 is unchanged or even decreased in BPH/5. A) Summary of free plasma PGF 
levels as determined by ELISA in non-pregnant (NP) and at different gestational 
stages of C57 and BPH/5 (n=4-6 per group). B) Summary of Pgf mRNA expression 
from placental tissue at different gestational days (n=5 per group). Data are expressed 
relative to C57 at e9.5. C) Summary of circulating sFLT1 levels as determined by 
ELISA in NP and at different gestational stages of C57 and BPH/5 (n=4-6 per group). 
D) Summary of real-time qPCR analysis of sFlt1 from placental tissue of C57 and 
BPH/5 at different gestational days (n=5 per group). *p<0.05 vs NP in matched strain; 
†p<0.05 vs. time-matched C57.  
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 time PCR. As shown in Figure 2.2B, placental Pgf mRNA was reduced in BPH/5 
compared to gestation-matched controls at e9.5 but not at other time-points, reflecting 
the plasma PGF data.  
           Since a decrease in VEGF and PGF levels can be accompanied by an elevation 
in sFLT1 levels in women with PE
1, 9
, next we compared the sFLT1 profile in BPH/5 
and C57 at early-, mid- and late-gestation. Circulating sFLT1 levels were increased at 
mid- and late-gestation in both strains relative to NP levels, however the increases in 
BPH/5 were either not different (late) or even decreased (mid) relative to C57 (Figure 
2.2C). Since the placenta is the major source of sFLT1 during pregnancy
27
, we further 
analyzed placental sFlt1 mRNA. Data in Figure 2.2D show that placental expression 
of sFlt1 increased throughout pregnancy in C57 starting at e12.5, and although the 
temporal profile in BPH/5 mirrors that of C57, mRNA levels were either not altered or 
even decreased (e14.5) in BPH/5.  
  Recently, soluble endoglin (sENG) has emerged clinically as a potentially important 
anti-angiogenic factor in PE
11
.  Therefore, plasma sENG levels were compared in 
BPH/5 and C57 at early- and mid-gestation. As shown in Figure 2.3, sENG was 
modestly elevated in BPH/5 at e9.5, but not at the other time-points examined. 
 
Adenoviral delivery of VEGF121 restores circulating free VEGF levels in BPH/5 
and rescues the angiogenic potential of serum from pregnant BPH/5. Based on our 
findings of decreased pro-angiogenic factors in BPH/5, along with the promise of 
VEGF121 as a therapeutic agent
5, 15, 16
, next we determined whether administration of 
an adenovirus encoding VEGF121 (Ad-VEGF) early in pregnancy in BPH/5 would 
normalize circulating free VEGF levels. We utilized an adenovirus rather than 
repeated daily injections of recombinant VEGF121
15, 16
 in order to effect stable, long-
term circulating levels of VEGF121
28
. As shown in Figure 2.4, tail vein injection of  
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Figure 2.3: Soluble Endoglin levels show slight increase at early gestation in 
BPH/5.  Summary of circulating sENG levels as determined by ELISA in non-
pregnant (NP) and at early- and mid- gestation C57 and BPH/5 (n=5-9 per group). † 
p<0.05 vs time-matched C57. 
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Figure 2.4: Adenoviral-mediated delivery of VEGF121 normalizes plasma VEGF 
levels in BPH/5. Summary of circulating free VEGF levels as determined by ELISA 
in non-pregnant (NP, 3 days post-injection), early or mid-gestation C57 and BPH/5 
mice that underwent tail vein injections of Ad-LacZ or Ad-VEGF. In pregnant mice, 
viral injections occurred on e7.5. NP: n=4-7 per group; early gestation: n=5-8 per 
group; mid gestation: n=5-10 per group. *p<0.05 vs NP in matched strain and 
treatment; †p<0.05 vs time-matched C57 Ad-LacZ; #p<0.05 vs. Ad-LacZ in matched 
strain and time-point. 
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Ad-VEGF in NP C57 and BPH/5 females increased plasma VEGF levels more than 
20-fold in both strains. Further, Ad-VEGF injected at e7.5 increased circulating VEGF 
in BPH/5 to levels that were comparable to gestation-matched C57 controls at both 
early- and mid-gestation (Figure 2.4). Free VEGF levels of Ad-LacZ-treated mice of 
both strains were similar to those without viral treatments (Figure 2.1A), confirming 
that the viral vector itself had no effect on circulating free VEGF levels.  
            To confirm that the Ad-VEGF-induced elevation in circulating free VEGF 
leads to functionally active VEGF, we performed a well established in vitro 
angiogenesis assay in HUVEC cells
9
 using serum collected from NP or pregnant C57 
and BPH/5 mice (e12.5) that had been treated with Ad-LacZ or Ad-VEGF (or no 
treatment) on e7.5. As seen in representative images and summary data in Figure 2.5, 
endothelial tube formation was significantly decreased with e12.5 serum from BPH/5  
that had received no viral treatment or had been injected with the Ad-LacZ vector. Ad-
VEGF treatment significantly enhanced tube formation elicited by BPH/5 serum 
compared to that of Ad-LacZ-treated controls, such that there were no differences in 
tube formation between serum of these mice and C57 controls (all treatments, Figure 
2.5). These results demonstrate that there was functional reconstitution of the 
angiogenic potential of serum from BPH/5 by systemic Ad-VEGF treatment.  
 
Ad-VEGF therapy early in pregnancy prevents the hallmark maternal PE 
symptoms and ameliorates fetal resorptions in BPH/5 mice. Next we tested the 
hypothesis that Ad-VEGF administered early in pregnancy in BPH/5 would ameliorate 
late-gestational hypertension and proteinuria in this model. NP female BPH/5 and C57 
mice were implanted with radiotelemeters for continuous measurement of BP before, 
during and after pregnancy
17, 18
. After 1 week recovery, 
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Figure 2.5: Ad-VEGF therapy rescues the angiogenic potential of BPH/5 serum 
as measured in an endothelial tube formation assay. A) Representative images of 
individual wells of HUVEC cells treated with serum collected from e12.5 C57 and 
BPH/5 that had undergone tail vein injections of Ad-LacZ or Ad-VEGF on e7.5. 
White bar (upper right) indicates a representative measurement of tube length. B) 
Summary of tube lengths normalized to 5% FBS in cells treated with serum from non-
pregnant (NP) mice or from e12.5 C57 and BPH/5 mice given no treatment (none) or 
administered Ad-LacZ or Ad-VEGF on e7.5. NP: n=8 per strain; no treatment and Ad-
LacZ: n=5-8 per group and strain; Ad-VEGF: n=5-12 per group and strain. *p<0.05 vs 
NP matched strain; † p<0.05 vs. C57 in matched treatment; # p<0.05 vs BPH/5 none 
or Ad-LacZ. 
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baseline BP was recorded for 3 days before timed strain-matched matings and the start 
of continuous BP measurements. On e7.5, BPH/5 and C57 mice underwent tail vein 
injections of Ad-VEGF or Ad-LacZ as above. As seen in Figure 2.6A and 2.6B, 
baseline mean arterial pressure (MAP) was significantly elevated in Ad-LacZ-treated 
BPH/5 compared to treatment-matched C57 (120±3 vs. 95±4 mmHg, p<0.05), 
consistent with our earlier reports that BPH/5 have mildly elevated BP before 
pregnancy
17, 18
. Importantly, neither viral vector altered baseline MAP in either strain 
(Figure 2.6A,2.6B). However, pregnancy caused a late-gestational rise in MAP over 
baseline (days 16-20) in Ad-LacZ-treated BPH/5 mice, which is characteristic of this 
strain
17, 18
, and this was prevented by Ad-VEGF therapy (Figure 2.6A). Notably, MAP 
returned to baseline following delivery in Ad-LacZ-treated BPH/5 mice, consistent 
with what we have shown previously
17, 18
 and with what occurs in women with PE
29
.  
MAP in C57 controls remained steady throughout pregnancy, and was unaffected by 
either viral vector (Figure 2.6B).  
         In a separate cohort of C57 and BPH/5 mice that had undergone Ad-VEGF or 
Ad-LacZ injections at e7.5, 24-hr urine samples were collected at mid- and late-
gestation and subjected to protein analysis. Proteinuria is detected only during late-
gestation in BPH/5 mice
17, 18
. These data were confirmed here, wherein urinary protein 
levels were significantly elevated in Ad-LacZ-treated BPH/5 compared to treatment-
matched C57 controls at late- but not mid-gestation (Figure 2.6C). Furthermore, 
similar to its effects on BP, Ad-VEGF administered early in pregnancy prevented 
development of proteinuria during late-gestation in BPH/5 (Figure 2.6C). Ad-VEGF 
did not alter urinary protein levels in C57 mice at either gestational time (Figure 
2.6C).  
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Figure 2.6: Adenoviral-mediated delivery of VEGF121 early in pregnancy 
prevents the hallmark maternal symptoms and rescues fetal demise in BPH/5. 
Summary of radiotelemetric measurements of mean arterial pressure (MAP) before, 
during and after pregnancy in BPH/5 (panel A) and C57 (panel B) mice. Ad-VEGF or 
Ad-LacZ were injected by tail vein on e7.5; n=6-8 for each strain and treatment. C) 
Summary of urinary protein levels at mid- and late-gestation in BPH/5 and C57 mice 
that had undergone virus injections on e7.5; n=6-12 per group at each time-point. D) 
Summary of incidence of fetal resorptions at e14.5 in C57 and BPH/5 mice that had 
undergone virus injections on e7.5; n=8-11 per group. E) Term litter sizes in each of 
the strains and virus treatment groups; n=11-18 litters per group. *p<0.05 vs baseline 
in matched strain; #p<0.05 vs BPH/5 Ad-LacZ; †p<0.05 vs C57 in matched treatment. 
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         To determine whether decreased VEGF production during early pregnancy is an 
important contributor to fetoplacental defects observed in BPH/5 mice
17, 19
, we 
examined several fetoplacental outcomes in BPH/5 and C57 mice treated with Ad-
VEGF or Ad-LacZ on e7.5 as above. Data presented in Figure 2.6D show that a third 
of fetoplacental units in BPH/5 mice treated with the control vector were resorbed, 
whereas resorptions in Ad-LacZ-treated C57 mice were extremely rare. These results 
are consistent with our earlier report of fetal resorption incidence in BPH/5
17
, and 
confirm that systemic delivery of adenovirus itself does not elicit resorptions. 
Importantly, Ad-VEGF reduced this fetal demise observed in BPH/5 by ~50% (Figure 
2.6D), which resulted in a significant increase in term litter size compared to Ad-
LacZ-treated mice (Figure 2.6E). On the other hand, VEGF therapy did not restore 
mid- or late-gestational placental or fetal weights in BPH/5 (Table 2.1). It should be 
noted that in C57 mice, Ad-VEGF treatment had no significant effect on fetoplacental 
outcomes except a small reduction in fetal weight at e14.5 (Figure 2.6 and Table 2.1).  
 
Potential effects of VEGF therapy: As circulating levels of VEGF significantly 
improved the hallmark symptoms of pre-eclampsia (Figure 2.6), and since the BPH/5 
have significant placental abnormalities associated with the development of the 
symptoms of pre-eclampsia 
17, 19
, we examined placentae from VEGF treated animals 
compared to LacZ controls.  An increase in circulating VEGF had no effect on overall 
placental morphology, with no change in labyrinth area, and global implantation depth 
(data not shown).  VEGF, however, had a positive impact on spiral artery remodeling 
in BPH/5, with a significant increase in the lumen diameter to outer diameter ratio in 
VEGF treated BPH/5 animals vs LacZ treated controls (Figure 2.7). VEGF therapy 
had no effect on spiral artery remodeling in C57 mice. 
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Table 2.1: Placental and fetal weights (mg) 
     
Gestation day and Sample  Treatment Strain Mean ± SEM n 
     
e14.5 Placental Weight (mg) Ad-LacZ C57 103.1±3.9 26 
  BPH/5 81.7±5.1 † 40 
 Ad-VEGF C57 109.4±4.2 19 
    BPH/5 93.4±3.8 † 13 
e14.5 Fetal Weight (mg) Ad-LacZ C57 293.4±12.9 20 
  BPH/5 196.4±6.8 † 29 
 Ad-VEGF C57 236.9±5.4 # 28 
  BPH/5 174.1±8.6 † 15 
     
e18.5 Placental Weight (mg) Ad-LacZ C57 91.3±3.1 35 
  BPH/5 105.3±4.1 † 26 
 Ad-VEGF C57 90.8±3.1 42 
  BPH/5 99.4±3.2 32 
e18.5 Fetal Weight (mg) Ad-LacZ C57 1168±19.0 35 
  BPH/5 1053±40.5 † 23 
 Ad-VEGF C57 1193±18.5 44 
    BPH/5 1022±22.3 † 29 
Data are expressed as mean ± SEM of n given in table for each treatment and strain. 
†p<0.05 vs. C57 in matched treatment, #p<0.05 vs C57 Ad-LacZ. 
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Figure 2.7: Adenoviral-mediated increase in VEGF has positive effects on spiral 
artery remodeling in BPH/5 mice.  A) Representative images of spiral arteries from 
sectioned placentae stained with Masson‟s Trichrome of samples taken at e12.5 from 
mice that received a tail vein injection of Ad-VEGF or Ad-LacZ at e7.5. B) Summary 
of measurements of the ratio of Lumen Diameter (LD) to Outer Diameter (OD). 
#p<0.05 vs BPH/5 Ad-LacZ; †p<0.05 vs C57 in matched treatment. 
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DISCUSSION 
The angiogenic imbalance theory of PE, first posited by Karumanchi and 
colleagues, has gained significant traction over the years. Their landmark study in 
2003 showed that the VEGF and PGF antagonist sFLT1 is upregulated in placentae of 
PE patients, and this is associated with increased circulating levels of sFLT1 and 
decreased free plasma VEGF and PGF
9
. A number of follow-up clinical studies 
supported these findings
1, 10, 30
, and an era began of determining whether these factors 
could be used as biomarkers and/or therapeutic targets in PE
30, 31
. However, more 
recent clinical data
13, 32
 and retrospective reviews of clinical studies such as that by 
Widmer et al.
33
 reveal a much more complex picture. In parallel to the clinical studies, 
basic research in animal models has yielded important proof-of-concept support for 
this hypothesis
9,14,15
. However, the experiments have involved exogenous delivery or 
experimental induction of sFLT1 and subsequent injections of VEGF121 to ameliorate 
sFLT1-mediated responses, which complicates interpretation about the endogenous 
role of these factors in PE. We employed an animal model that spontaneously 
develops a PE-like syndrome to rigorously test the angiogenic imbalance hypothesis in 
the laboratory.  
           First, we found that the increase in plasma free VEGF levels that occurs 
normally during early- and mid-gestation in murine (C57) pregnancies is significantly 
attenuated in BPH/5. This appears to be due at least in part to decreased translation of 
VEGF mRNA in the placenta. The decreased free VEGF levels observed in BPH/5 
mice is consistent with human disease data
9
, however our finding of diminished 
placental VEGF protein is in contrast with some reports in PE patients in which VEGF 
protein and total VEGF circulating levels may actually be higher than in normal 
pregnancies (but this is compromised by excess sFLT1)
34
. Second, our results show 
that the normal pregnancy-induced increase in circulating free PGF in C57 is limited 
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to early gestation, which mirrors the temporal expression pattern of this growth factor 
in murine placenta observed in this study and others
35
. Placental expression and 
plasma free PGF are also markedly blunted in BPH/5 pregnancies. Third, unlike the 
increased expression and circulating levels of sFLT1 that have been suggested as a 
causative factor in PE in women
1, 9, 10
, this anti-angiogenic factor is either unchanged 
or even decreased in BPH/5 placentae and plasma relative to controls. This suggests 
that while there is marked angiogenic imbalance in the BPH/5 model, it may be due to 
decreased production of pro-angiogenic VEGF and PGF independent of sFLT1-
mediated sequestration of these factors. However, it should be noted that sFLT1 is 
now known to have at least 4 isoforms, and the isoform that is most dominantly 
expressed in human PE placentae is not expressed in mice
36
.  
Fourth, sENG is modestly elevated transiently at early gestation in BPH/5, suggesting 
it is not a major contributor to the PE-like syndrome in BPH/5. Finally, we show that 
decreased expression of VEGF is functionally linked to the development of fetal 
demise and the maternal PE-like syndrome in BPH/5 mice since early (e7.5) systemic 
delivery of Ad-VEGF normalized circulating free VEGF, rescued the angiogenic 
capacity of serum from pregnant BPH/5, decreased fetal resportions and prevented the 
hallmark late-gestational hypertension and proteinuria observed in this model. 
          Although it is widely accepted that the placenta is the major source of 
angiogenic factors during pregnancy
19, 25, 35
, it has been difficult to directly link 
changes observed in plasma from PE patients to dysregulation of these genes in the 
placenta due to lack of availability of placental tissue from PE patients at early time 
points. However, a few studies have demonstrated that cytotrophoblasts from 
preeclamptic patients show lower staining of VEGF and its receptors, suggesting 
dysregulation of angiogenic genes in the placenta
34, 38
. Our data highlight the 
possibility of post-transcriptional regulation of VEGF in the placenta because while 
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there is a marked decrease in VEGF protein levels in BPH/5 placentae, mRNA levels 
of VEGF are not significantly changed at any time-point compared to controls. Several 
mechanisms for post-transcriptional regulation of VEGF in other tissues have been 
postulated, including down-regulation by microRNAs and translational regulation by 
cMyc
26
.  In addition, hypoxia is known to stabilize Vegf mRNA,
39
 and a stress-
responsive „switch‟ in the 3‟ UTR of Vegf has been shown to regulate its expression 
during hypoxia
40
. This is interesting since it has been postulated that PE is associated 
with premature breach of the trophoblast shell in early placental development and a 
subsequent burst of hyperoxia in the developing placental tissue
41
. Although decreased 
PGF in BPH/5 appears to be due to decreased placental transcription during early 
gestation, similar to VEGF, PGF regulation by miRNA-mediated repression of 
translation cannot be ruled out. Our unpublished data shows that in early-gestational 
BPH/5 placentae, there is marked upregulation of several microRNAs that are known 
to bind and repress translation of both VEGF and PGF mRNA (Zhou, Guruju, Woods, 
Sharma and Davisson, unpublished results).  
            The mechanisms by which decreased circulating free VEGF or PGF during 
early and mid-gestation result in the multi-system dysfunction observed in PE are not 
yet fully understood. Given their importance in angiogenesis and vascular remodeling 
during fetoplacental development, as well as in maintaining maternal cardiovascular 
and renal function, there are several possibilities. First, a decrease in placental 
synthesis and secretion of VEGF and PGF by villous cytotrophoblasts, fetal 
macrophages and fetal fibroblasts may lead to decreases in vasculogenesis and 
angiogenesis, causing poor placentation
25, 42
. Early defects in placentation due to 
decreased production of these pro-angiogenic factors could cause the so-called “Stage 
1” of the disease, characterized by reduced fetoplacental perfusion and a reduction in 
spiral artery remodeling, placental oxidative stress and inflammation
42, 43
.  Preliminary 
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placental morphological analyses suggest VEGF has an effect at the level of spiral 
artery remodeling (Figure 2.7).     As spiral artery remodeling is decreased in BPH/5, 
one might speculate a decrease in uterine natural killer (NK) cells, as they are shown 
to be involved in this process
44, 45
. Through secretion of angiogenic factors VEGF, 
PGF and angiopoeitin-II, NK cells are important mediators of early placental 
development, including trophoblast invasion and facilitating spiral artery 
remodeling
46
. Though a preliminary analysis of NK cells has been carried out in 
BPH/5 showed no global reduction in the number of these cells
19
, perhaps their 
distribution or activation is not optimal.  Additionally, recent work has demonstrated 
several sup-populations of uNK cells by histology 
47, 48
 which can be classified based 
on size and degree of granulation as well as DBA lectin and PAS staining status 
(positive or negative).  Further classification and examination of uNK cells in BPH/5 
is warranted. Shallow trophoblast invasion, deficient spiral artery remodeling, and low 
levels of angiogenic factors present in BPH/5 placentae (Figure 2.1, 
19
), may argue a 
potential defect in uterine NK proliferation or differentiation
49
.  If this hypothesis were 
true, perhaps by increasing circulating levels of VEGF, as performed in this study, the 
deficiency of angiogenic factors as a result of the defective NK population is bypassed 
and spiral artery remodeling improved to normal levels.  Indeed, it is interesting to 
speculate that Ad-VEGF, by ameliorating poor placentation and spiral artery 
remodeling in the BPH/5 model, leads to reduced fetal resorptions as reported in 
Figure 2.4D, and that this may be the critical upstream event in Ad-VEGF‟s beneficial 
effects on maternal symptoms in this model. It should also be noted that another splice 
variant of the gene encoding a soluble form of the VEGF receptor-2 has recently been 
identified and shown to inhibit angiogenesis
50
. It will be intriguing to determine if this 
isoform is altered in BPH/5 placentae.  
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         In addition to the placenta, angiogenic factors play an important role in various 
other organ systems. For example, VEGF expression is critical to maintaining the 
fenestrated and sinusoidal endothelium of the kidney and choroid plexus of the brain 
and liver, three distinct areas that are affected in PE patients
1, 51
. Podocytes, renal 
epithelial cells that form the outermost glomerular filtration barrier, synthesize large 
amounts of VEGF, which is required for development and function of the glomerular 
filtration barrier
51, 52
. Decreased circulating or local podocyte levels of VEGF could 
lead to damage of glomerular endothelium and increased protein secretion into the 
urine
1, 51
. VEGF is also known to regulate vascular permeability, and dysregulation of 
this process can result in edema, another distinct feature of PE
1
. Furthermore, evidence 
from anti-angiogenic cancer clinical trials using anti-VEGF antibodies shows that 
VEGF antagonism results in hypertension, glomerular endotheliosis and proteinuria,
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again reinforcing the potential role of decreased VEGF in the development of 
gestational hypertension and proteinuria. Given the powerful effects of early Ad-
VEGF treatment on BPH/5 fetal outcomes and maternal endpoints in this study, it will 
be important to determine the site(s) and mechanisms by which increased levels of this 
pro-angiogenic factor mediates its effects.  
            Emerging evidence suggests that decreased levels of circulating VEGF may 
also contribute to oxidative stress-induced endothelial dysfunction. Recent work from 
Granger and colleagues has shown that exogenous delivery of recombinant sFLT1 into 
pregnant rats results in reduced plasma free VEGF levels, increased vascular oxidative 
stress, decreased NO-dependent vasorelaxation and increased blood pressure
54
. 
Previous work from our laboratory has shown that increased reactive oxygen species 
scavenging by Tempol starting before and continuing throughout pregnancy 
ameliorates fetoplacental defects and development of PE symptoms in BPH/5 model
18
. 
These results, along with our current findings of decreased placental and plasma free 
70 
 
VEGF in BPH/5 and our previous data showing that BPH/5 exhibit late-gestational 
endothelial dysfunction
17
 suggest that dysregulation of VEGF production in this model 
may lead to maternal oxidative stress and endothelial dysfunction. Certainly many 
previous studies have implicated both increased oxidative stress and angiogenic 
imbalance in the development of PE, however the pathogenic mechanisms have 
mostly been considered in parallel
42, 43, 55
.  The studies discussed above suggest a 
possible connection between these two pathways.   
           We have shown that an angiogenic imbalance in BPH/5 mice precedes the 
onset of maternal PE-like symptoms in this model, and this imbalance is likely due to 
decreased placental synthesis and circulation of VEGF and PGF independent of 
increased antagonism by sFLT1. Furthermore, our studies suggest a causal link 
between decreased VEGF levels and the development of fetoplacental defects and 
maternal PE-like symptoms since early viral delivery of VEGF121 was sufficient to 
reduce fetal resorptions and prevent late-gestational hypertension and proteinuria in 
this model. Since fetal loss occurs in advance of hypertension and proteinuria in this 
model, it is interesting to speculate that Ad-VEGF‟s beneficial effects on fetal status 
contributed to amelioration of the maternal syndrome in this study. We believe the 
BPH/5 model will provide a unique opportunity to now examine the precise molecular 
underpinnings of changes in the angiogenic profile in the context of PE.  
 
*** Figures 2.4 and 2.6 as well as Table 2.1 reflect experiments performed by D. 
Hoffmann and C. Weydert, co-authors of this manuscript.****  
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CHAPTER THREE: 
GENE EXPRESSION PROFILING OF SONOGRAPHICALLY 
PHENOTYPED FETOPLACENTAL UNITS REVEALS A BROAD ARRAY OF 
DIFFERENTIALLY REGULATED PATHWAYS IN THE BPH/5 MOUSE 
MODEL OF PRE-ECLAMPSIA 
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SUMMARY 
Pregnancies in BPH/5, a murine model of PE, are characterized by abnormal 
placentation and progressive fetal loss. To identify at-risk embryos in utero, ultra-high 
frequency ultrasound (VEVO 770) was used to phenotype BPH/5 embryos at e10.5. 
Pregnant BPH/5 and C57were anesthetized, the uterine horns exteriorized, and 
sonographic data collected from each embryo using a 40MHz scanhead. Three distinct 
fetoplacental phenotypes emerged in BPH/5 when compared to C57: Class I (normal 
HR and development); Class II (slow or irregular HR, reduced size); Class III (no 
development past e7.5). Scored fetoplacental units were then dissected and tissues 
from each of the three classes of BPH/5, as well as C57 implantation sites, were 
collected. Total RNA was extracted and gene expression microarray experiments were 
run. Separate arrays were used comparing each BPH/5 class to a C57 reference, and 
genes were considered dysregulated with >1.5-fold change and p<0.05. A total of 
2350 dysregulated genes were identified across the three BPH/5 classes, with Class II 
showing the greatest proportion of differentially expressed genes. The more 
developmentally challenged classes showed dysregulation in functional pathways of 
angiogenesis, development and apoptosis. Review of the gene lists revealed that 6 
different imprinted genes were among the dysregulated genes, with 4 of paternal 
origin (insulin growth factor 2, delta-like 1, paternally expressed gene 3 and the amino 
acid transporter Slc38a4) and 2 of maternal origin (H19 and Decorin). Together, these 
data reveal that a significant proportion of BPH/5 fetoplacental units exhibit 
compromised development and health at e10.5, and this is associated with marked 
gene dysregulation, including several imprinted genes.  
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INTRODUCTION 
Pre-eclampsia (PE) is a pregnancy-associated disorder affecting 8-10% of 
women worldwide. It is characterized by new onset high blood pressure and 
proteinuria late in gestation. Fetoplacental abnormalities often complicate PE 
pregnancies.  Early onset PE is associated with increased risk of intra-uterine growth 
restriction (IUGR) of the fetus1. Additionally, pregnancies complicated by severe PE 
have an increase risk of fetal mortality2. Placentae from PE pregnancies often show 
shallow trophoblast invasion into the maternal decidua and reduced spiral artery 
remodeling3, 4. Though the etiology of PE remains unknown, major recent hypotheses 
include abnormal placentation and angiogenic imbalance5. However, there are still 
very few treatment options beyond early delivery of the placenta and fetus.   
Several years ago we described the BPH/5 model, a murine strain that 
spontaneously develops a syndrome that bears close resemblance to human PE. These 
mice develop pregnancy-induced hypertension, proteinuria, and placental defects with 
time-courses similar to the human condition6, 7.  BPH/5 is also a model of intrauterine 
growth restriction and fetal loss6, 7. Determining the cause of fetal demise in this 
model, and how this may relate to the development of the maternal syndrome in later 
pregnancy could provide very important clues in our understanding of the 
pathophysiology of PE. 
The use of gene expression profiling of cells and tissues has become a major 
tool for determining disease progression, identification of diagnostic or prognostic 
biomarkers and classification of diseases. In recent years, this technology has been 
used to investigate the molecular mechanisms of normal placental development in 
human and mouse8, 9 as well as placental abnormalities in human pregnancies 
complicated with PE10-17. A number of differentially regulated genes were identified as 
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potential biomarkers for predicting PE, however, a limitation of these human studies 
comes from the scarcity of samples collected at different gestational time points. The 
molecular profile of term PE placentae provides a snapshot of endpoint dysregulated 
pathways, however it does not aid in identifying differentially expressed genes in what 
is likely a long cascade of gestational events leading up to manifestation of the 
disease.    
A significant advancement in the field of PE research could come with the 
understanding of early pathological events that lead to the maternal syndrome. The 
BPH/5 mouse model provides a unique tool for understanding early fetoplacental 
defects that may underlie the development of PE later in gestation. Since some but not 
all BPH/5 fetuses succumb during gestation, we turned to ultra-high frequency 
ultrasound in order to track fetoplacental status in utero.  Clinical ultrasounds have 
long been used to monitor human pregnancies, however the resolution of these 
systems is limited in the study of murine pregnancy. The availability of dedicated 
ultrasound imaging systems for rodents, such as the VEVO 770 (Visualsonics), have 
provided unique opportunities to examine developmental defects in fetoplacental units 
starting early in gestation.   With these systems, transducers capable of operating at 
eight times higher frequency than clinical ultrasounds have allowed researchers to 
visualize miniature structures in a non-invasive manner (in utero)18. With these 
improvements in resolution, murine embryos can be imaged as early as e5.5, with 
embryonic heart rates detected as early as e9.519, 20.  In this study, we hypothesized that 
BPH/5 fetoplacental units would exhibit differential gene expression at early gestation 
(e10.5). Examining BPH/5 fetoplacental units via ultra-high frequency ultrasound 
provides a powerful tool to assess embryonic health in utero and provides a platform 
for molecular characterization and understanding the genetic underpinnings of fetal 
demise in this model. We focused on this timepoint since previous work in our group 
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shows increased incidence of fetal demise starting at mid-gestation, coincident with 
the development of PE-like symptoms in this mouse model6, 7. By focusing earlier in 
gestation, our goal was to elucidate potential pathways underlying fetal demise, and 
perhaps the PE-like syndrome in this model.  Using Vevo 770 for ultra-high frequency 
ultrasound, we scored and separated embryos into three categories based on fetal 
health and development. Using RNA isolated from these three classes of fetoplacental 
units, along with gestation-matched C57Bl/6 units, we performed genome-wide 
expression profiling using DNA microarray technology.  
 
METHODS 
Ultra-high frequency ultrasonagraphic analysis of BPH/5 and C57 mouse feto-
placenta units. Strain-matched matings were set up for C57Bl/6 (C57) controls and 
BPH/5 mice.  The day vaginal plug was detected was denoted e0.5.  Initial 
experiments showed that gestation day 10.5 was the earliest time point in which the 
greatest variation in embryonic health was examined prior to fetal death and necrosis 
(data not shown).  Pregnant BPH/5 and C57 females at e10.5 were anaesthetized with 
2% isofluorane and the abdominal hair was chemically removed as described in Slevin 
and colleagues21.  Maternal physiology was closely followed by monitoring core body 
temperature, heart rate and respiration rates.  Briefly, a ventral incision was made and 
the uterine horns were exteriorized and each individual embryo was interrogated using 
a 40MHz frequency scanhead (Visualsonics VEVO 770).  Fetal and maternal heart 
rates (HR) were measured using pulse-wave Doppler (expressed as fetal/maternal 
HR), and crown-rump measurements were taken when the orientation permitted the 
maximum distance between head and tail (as described in 22).   Fetuses were placed in 
one of 3 categories: Class I (normal HR and development); Class II (slow or irregular 
HR, reduced size); Class III (no embryonic dvelopment, HR often not detected but not 
85 
 
necrotic).  After embryos were categorized, the female was quickly euthanized via 
cervical dislocation and individual implantation sites (fetus, placental tissue and 
surrounding uterine wall) were excised and placed in RNA stabilizing RNAlater 
(Qiagen) and stored at -80ºC for future RNA extraction (see below).  All animal 
protocols were approved by the Cornell University Animal Care and Use Committee. 
 
Immunohistochemistry. Isolectin staining was performed as described previously 6.  
Briefly, implantation sites were fixed in 10% formalin before paraffin embedding 
using a standard procedure. Paraffin sections were cut at 5μm, and stained using 
Isolectin-B4 staining (1:125, Vector Laboratories), which labels basement membranes.  
Sections were counterstained with DAB+ (Dako) and photographed. 
 
Total RNA extraction. Total RNA was isolated from the entire fetoplacental unit 
using QIAGEN RNeasy Mini kit (QIAGEN) in accordance with manufacturer‟s 
protocols. Total RNA was quantified with NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific). The quality and integrity of total RNA were assessed using 
Agilent 2100 Bioanalyzer (Agilent Technologies). The RNA integrity number (RIN) 
equal to or higher than 9 was acceptable for microarray and real time qPCR analysis. 
 
DNA microarray. The microarray experiments were performed with a dual-channel 
reference23 design in which the C57 mouse fetoplacental units were used as a 
reference. Array analysis was carried out with a subset of embryos collected from 
three pregnancies where a BPH/5 female carried embryos from each class (I, II, and 
III). Three such litters were used for these studies. C57 embryos (all Class I) were 
used as controls.  Labeling was carried out using the indirect cDNA labeling method 
in which 20µg of total RNA was labeled with Cy5 or Cy3 and purified prior to 
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hybridization on the array (cDNA synthesis using Superscript III, Invitrogen, 
purification with columns from QIAGEN).  The labeling efficiency and quantification 
of Cy3 and Cy5 dye were assessed on NanoDrop ND-1000. Prior to hybridization, the 
mouse OneArray™ with 29,922 mouse genome probes and 1880 experimental control 
probes which are highly sensitive to 70-mer sense-strand polynucleotide probes 
(Phalanx Biotech) were prehybridized for 1 hour followed manufacturer‟s instructions. 
The labeled cDNA was resuspended in mouse OneArray hybridization buffer and the 
arrays were incubated in hybridization chambers (Corning) and hybridization was 
performed for 16 to 20 hours at 42°C. Each array was scanned with the GenPix 4000B 
microarray scanner (Molecular Devices) at two channels of wavelengths, 532 and 
635nm. The scanned images were analyzed and each spot quantified using Genepix 
Pro 6.0 program (Molecular Devices).  
 
Microarray data analysis. For the microarray data normalization and differential 
expression analysis, R software 2.6.0 (http://www.r-project.org/) and LIMMA (Linear 
Models for Microarray Data) software was used. The p-values were adjusted for 
multiple test corrections across all genes and comparisons with the Benjamini-
Hochberg method to control for false-discovery rate (FDR) at less than 5% with 
moderate stringency with a fold change cutoff of ≥ 1.5 or ≤ -1.5.  These criteria were 
used as a threshold to determine genes with significant differential expression.   
 
Real Time Quantitative PCR validation. A number of differentially expressed genes 
from the microarray study were validated with real-time quantitative PCR. First strand 
cDNA was prepared using High Capacity cDNA Reverse Transcription it (Applied 
Biosystems) followed the manufacturer‟s protocol. An equivalent to 25 ng of total 
RNA was used in real time quantitative PCR. The primers for real time quantitative 
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PCR (see Table 3.1) were designed. The housekeeping gene, β-actin, was used as an 
internal control for normalization. Real-time PCR reactions were performed in a 96-
well plate with a total volume of 25 µl containing 1X Power SYBR Green PCR 
Master Mix and the ABI 7500 Fast Real-Time PCR System (Applied Biosystems).   
The quantification of gene expression was analyzed with ΔΔCt method24. The relative 
expression of each gene with fold changes in mRNA was calculated as 2
-ΔΔCt
.  
 
Functional Analysis 
Gene Ontology analysis. To interpret the function of differentially expressed genes in 
Class I, II and III of BPH/5 mouse fetoplacental units associated with the biological 
processes, the analysis tool, Database for Annotation, Visualization and Integrated 
Discovery DAVID (http://david.abcc.ncifcrf.gov/)25, 26 was applied to assess whether 
the gene ontology terms occurred more frequently than expected by chance in the set 
of genes dysregulated in BPH/5. The Functional Annotation Tool in DAVID was 
performed with the medium stringency setting (Kappa similarity term overlap ≥ 3 and 
threshold of 0.85; classification multiple linkage threshold of 0.5).  For DAVID 
analyses, the significance of over-representation of functional categories was assessed 
with a p-value (from a modified Fisher Exact test) and with Benjamini correction of 
0.05. This criterion was used to determine significance of enriched GO terms. All 
results are ranked based on p values and processes (Gene Ontology “Biological 
Process” category) with the highest enrichment are presented. 
Network analysis-IPA.Ingenuity Pathway Analysis (IPA) assigns biological functions 
to genes using the Ingenuity Pathways Knowledge Base (Ingenuity Systems). IPA 
analysis was performed on array data from BPH/5 Class I, II and III compared to C57 
(IPA version 8).  The top 15 most dysregulated functional pathways were recorded 
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and the number of dysregulated genes within those pathways noted.  Finally, network 
analysis was performed on the top ranking networks within each class.   
 
RESULTS  
BPH/5 fetoplacental units show a range of fetal health at e10.5.  Previous studies 
show progressive fetal loss and a wide variation in fetoplacental health status within 
BPH/5 litters6, 7.  Since we hypothesize that mRNA expression will vary with 
fetoplacental health status, we used ultra-high frequency ultrasound to phenotype and 
classify fetoplacental units prior to gene profiling.  Initial experiments using 9 BPH/5 
litters showed a wide range of fetal status at e10.5 compared to C57 gestation matched 
controls. Embryos were scored into three separate classes based on embryo size 
(crown-rump measurements), fetal heart rate, and cardiac development (Figure 3.1 A-
D).  Approximately 65% of BPH/5 fetuses were categorized as Class I which represent 
the healthiest of BPH/5 embryos (Figure 3.1E), with similar heart rate (Figure 3.1G) 
and developmental profiles as C57 time-matched counterparts, although they still 
showed reduced crown-rump measurements compared to C57 (Figure 3.1F). Class II 
embryos represent 23% of BPH/5 embryos, and they showed developmental delay in 
cardiac structure, bradycardic or irregular HR and extreme IUGR compared to both 
healthy littermates (Class I), and C57 controls (Figure 3.1 E-G). Finally, 12% of 
BPH/5 fetuses were Class III, with severely retarded development (although not 
necrotic) (Figure 3.1E). 
 Next we examined the histomorphology of different classes of fetoplacental 
units by isolectin staining to compare placental development. Class I (Figure 3.1H) 
embryos show normal formation of placental zones of labyrinth, spongiotrophoblast 
and decidua, whereas Class II (Figure 3.1I) embryos lack a unified formation of 
labyrinth, and Class III (Figure 3.1J) embryos show lack of placental development, 
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Table3.1. Primer Pairs Used for Real Time PCR Validation of Microarray Data 
Gene Accession 
No. 
Primer sequence (5’ to 3’) Tm 
(°C) 
Amplicon 
size (bp) 
AFP NM_007423 AACAGGAGGCTATGCATCACCAGT 60.0 ºC 182 
TGCTCCTCTGTCAGTTCAGGCTTT 60.0 ºC 
Timp4 NM_080639 ACACGCCATTTGACTCTTCCCTCT 60.1 ºC 192 
AGCCACAGTTCTGGTGGTAGTGAT 59.7 ºC 
SP7 NM_130458 TGCAGCAAATTTGGCGGCTCTA 59.8 ºC 141 
TCCATTGGTGCTTGAGAAGGGA 58.2 ºC 
Ccnd2 NM_009829 ACGCATGTGGTGCCTGTTCAAA 59.9 ºC 142 
ATGTTGCAGGTACGCACACTCT 58.7 ºC 
Thbs2 NM_011581 ATGCAGCCTGGGCAAATGTGAT 59.8 ºC 195 
TCACGCTGACAGGGTTTGGTTT 59.2 ºC 
TNFRSF11B NM_008764 CCACAATGAACAAGTGGCTGTGCT 60.0 ºC 155 
TAGGTAGGTGCCAGGAGCACATTT 59.8 ºC 
Sfrp4  
 
NM_016687 TCATCACCAATTCCTCCTGCCAGT 60.1 ºC 182 
TGTTCTCTGCTGTTCCTGAAGCCT 60.0 ºC 
Adam12 NM_007400 AAGAATTGCCACTGTGAAGCCCAC 59.9 ºC 158 
ACAAATCCAGCAGCAAGCAGACAC 60.0 ºC 
Adam19 NM_009616 ATGGACCACAAGAGGAAGCCAAGA 60.0 ºC 176 
AAAGGTGCTCGTTCTTCTCCAGGT 60.0 ºC 
Casp2 NM_007610 TACATGACCAGACCGCACAGGAAA 60.0 ºC 130 
ACACCATAGATGCCACCTTCCACA 60.0 ºC 
Il1rl1 NM_001025602 ACACTTGTCAATTCACACACGCGG 59.9 ºC 222 
TAATCTGCCACAGGACATCAGCCA 60.0 ºC 
Itgb7 NM_013566 CACGGATACTGCAAATGCAACCGT 59.9 ºC 115 
ACTCTGCACAATCCCTGTACTGCT 59.9 ºC 
Cldn1 NM_016674 TGCAAAGTCTTCGACTCCTTGCTG 59.2 ºC 126 
CATGCACTTCATGCCAATGGTGGA 60.0 ºC 
Il1r2 NM_010555 AGATGAGCCAAGGATGTGGGTGAA 60.1 ºC 115 
CATTTGCTCACAGTGGGATGCGTT 60.0 ºC 
Tnfrsf22 NM_023680 TGTTTGGCTTCTTCTGCAGCTTGG 60.0 ºC 162 
ACCAGTATTCACCAGCGGGACATT 60.2 ºC 
Adamts5 NM_011782 ACTACGATGCAGCCATCCTGTTCA 60.1 ºC 187 
TGAGAAAGGCCAAGTAGATGCCCA 60.0 ºC 
Cyp39a1 NM_018887 TGCAGGTCATTCTGGAACCCTCTT 60.0 ºC 243 
CCTGCAGTGCCAAACACAGAAGAT 59.6 ºC 
Ccnd1 NM_007631 GCTGCAAATGGAACTGCTTCTGGT 60.1 ºC 199 
TACCATGGAGGGTGGGTTGGAAAT 60.0 ºC 
β-Actin NM_007393   TCGTACCACAGGCATTGTGATGGA 60.1 ºC 200 
TGATGTCACGCACGATTTCCCTCT 60.2 ºC 
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Figure 3.1: Ultrasonographic analysis reveals three classes of fetoplacental status 
in BPH/5 litters. Representative sonograms showing  C57 controls (A) and three 
classes of embryos at e10.5 (B-D, Class I-III respectively). Caliper placement for 
crown- rump measurements illustrated in Class I (panel B). (E) Summary of the 
proportion of BPH/5 fetuses comprising each of the three classes (n=9 litters).  (F) 
Summary of fetal HR (relative to maternal HR) reveals bradycardia in Class II (n=6) 
compared to Class I (n=26) and C57 (n=21).  (G) Summary of crown rump length 
reveals reduced fetal size of Class I (n=20) and Class II embryos (n=5) compared to 
Class I  and C57 (n=13).  Representative images from isolectin stained fetoplacental 
units show a range of placental development from easily defined placenta in Class I 
(H),  minimal placental definition in Class II (I), and no placental development in 
Class III (J).  *p<0.05 vs C57, † p<0.05 vs Class I H, heart, U, umbilical cord, P, 
placenta. 
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and only a decidual response with a few scattered giant cells. 
 
Scored fetoplacental units show unique genetic profiles. As three distinct classes of 
BPH/5 embryos are apparent at e10.5, gene expression microarray analysis was 
performed in these classes compared to C57 controls.  The entire fetoplacental unit 
was used to remain consistent among all classes; as there is no embryo/placental 
development in Class III, we examined the entire implantation site including embryo, 
placenta and associated uterine tissue.  
We performed a genome-wide expression study and identified 808, 1901 and 
777 dysregulated genes in Class I, II and III, respectively, with the criteria of p <0.05 
and a fold-change greater than 1.5 compared to C57 controls (false discovery rate of 
less than 5%). The Venn diagram used to compare the expression pattern of all classes 
(Figure 3.2) showed that 287 genes were unique in Class I, 1098 genes were unique in 
Class II and only 104 genes were unique in Class III. A total of 275 genes were 
common in all three classes.   
 
Microarray data validation with Quantitative Real Time RT-PCR. To validate the 
microarray expression profile, we performed real-time reverse transcription PCR for 
16 genes, of which 9 are up-regulated and 7 down-regulated identified by microarray 
(Table 3.2).   Validation confirmed the directionality of gene expression with slight 
differences in expression magnitude reflective of the difference between sensitivity of 
real time PCR with microarray27.  
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Figure 3.2: Microarray analysis revealed differential dysregulation of genes in 
BPH/5 fetoplacental units from each of the three embryonic health classes 
compared to C57 controls.  Venn diagram summarizing the number of dysregulated 
mRNAs unique to each class and shared between Class I,II, and III. All genes 
considered have greater than 1.5-fold change difference from C57 fetoplacental 
controls, n=3, p<0.05 vs C57.
 
 
Table 3.2: Validation of microarray data from classed fetoplacental units with real time PCR 
  Class I Class II Class III 
Gene Accession 
Number 
Gene 
Symbol 
Microarray 
 
Real Time 
PCR 
Microarray Real Time 
PCR 
Microarray Real Time 
PCR 
NM_007423 AFP -3.1±1.2 -1.1±0.3 -5.1±0.3 -21.6±1.3 -21±2.6 -8.7±0.7 
NM_080639 Timp4 -6.3±0.2 -2.0±0.1 -9.5±0.7 -15.2±0.8 -10.2±1.5 -6.1±1.0 
NM_130458 SP7 -5.5±0.3 -1.5±0.4 -3.6±0.8 -7.9±0.6 -2.8±0.6 -2.5±0.4 
NM_009829 Ccnd2 -1.8±0.7 -1.7±0.1 -2.4±0.3 -2.7±0.7 -3.1±0.5 -2.1±0.4 
NM_011581 Thbs2 2.2±0.6 2.7±0.5 3.4±0.8 9.8±0.6 3.8±1.0 8.5±1.1 
NM_008764 TNFRSF11B 2.4±0.6 8.0±0.6 4.4±0.6 9.3±0.5 4.0±0.9 12.3±0.3 
NM_016687 Sfrp4 2.1±0.4 3.9±0.2 3.0±0.3 9.3±0.8 2.6±0.4 6.9±0.3 
NM_007400 Adam12 2.1±0.5 6.0±0.5 3.2±0.4 6.9±2.0 2.7±0.3 6.0±0.5 
NM_009616 Adam19 3.0±0.3 3.2±1.0 2.6±0.2 3.2±0.5 3.1±0.5 2.8±0.6 
NM_007610 Casp2 -2.4±0.4 -1.6±0.04 -3.3±0.4 -2.8±0.2 -2.6±0.6 -2.1±0.2 
NM_001025602 Il1rl1 -5.4±0.2 -7.1±0.02 -5.1±0.7 -9.7±0.02 -4.8±0.9 -8.5±0.08 
NM_013566 Itgb7 2.4±0.3 5.9±1.2 2.1±0.5 4.9±0.8 2.7±0.6 4.9±1.0 
NM_016674 Cldn1 3.1±0.2 6.7±2.0 3.2±0.5 5.9±1.1 3.6±0.7 8.1±2.0 
NM_010555 Il1r2 3.7±0.2 4.7±1.2 7.1±1.0 7.8±0.7 6.5±1.4 7.5±0.7 
NM_023680 Tnfrsf22 -2.7±0.5 -1.8±0.4 -2.4±0.4 -1.7±0.2 -2.0±0.4 -1.4±0.3 
NM_011782 Adamts5 2.6±0.3 4.0±0.4 4.8±0.2 4.9±0.3 4.3±0.5 5.4±1.7 
NM_007631 Ccnd1 -1.3±0.4 -2.5±0.4 -2.4±0.4 -5.5±0.2 -2.5±0.6 -6.1±0.2 
Values are given as fold change vs C57 ± SEM. Negative values denote down regulated genes.  
9
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Gene Ontology analysis reveals common dysregulated pathways in classed BPH/5 
fetoplacental units. To further analyze the data gathered by microarray, we 
performed gene ontology (GO) analysis using DAVID (Database for Annotation, 
Visualization and Integrated Discovery) to investigate how these dysregulated genes 
were classified into biological or physiological processes. Functional annotation 
clustering analysis was performed on all genes in Class I, Class II, Class III 
separately, as well as common genes shared in all classes. The GO analysis of the 
three functional groups with the highest enrichment scores are presented in Table 3.3, 
with selected genes from within those functional groups listed. Class I BPH/5 
fetoplacental units show dysregulation in cell adhesion, development (predominantly 
bone development) and extracellular matrix organization (Table 3.3).  In Class II, the 
biological processes with a markedly increased enrichment score include angiogenesis 
and blood vessel development, apoptosis and development.  Finally, in Class III, the 
profile of biological processes resembles Class II with clusters in the processes of 
angiogenesis, apoptosis and embryonic development.  Finally, the functional group 
analysis for genes common to all three classes show dysregulation in pathways 
involved in response to reactive oxygen species, extracellular matrix organization and 
apoptosis. 
 
Gene network analysis-IPA analysis. An alternative method of examining the 
functional significance of dysregulated genes is to examine their function and 
grouping in Ingenuity Pathway Analysis, where genes are grouped into functional or 
disease-associated pathways. The top functional pathways generated from the unique 
genes dysregulated in each class are represented in panel A-C of Figure 3.3.  The 
height of each bar graphs shows the significant degree of dysregulation of that
 
 
Table 3.3: GO analysis of classed fetoplacental units using DAVID software.                                                                                   
Top three scoring processes are listed for each group, with selected dysregulated genes listed for each functional group.
BPH/5 
Class 
Functional group ; Cluster 
Enrichment 
score 
Selected Genes 
I Cell adhesion ; cell-substrate adhesion, cell-matrix adhesion, integrin- 
mediated signaling pathway 
 
2.74 CTGF, NPNT, ITGB7, ITGB5, ITGB3, 
ITGB1, ITGBL1, ADAM17, ADAMTS1, 
ADAM19,ADAMTS2 
I Development ; bone development, skeletal system development, 
ossification, cartilage development 
 
2.25 MMP9, COL5A2, SP7,COL1A1,BMP7, 
BMP8A, 
I Extracellular Matrix ; extracellular matrix organization, collagen fibril 
organization, extracellular structure organization 
 
2.03 MMP9, SERPINH1,TGFB2,  COL5A2, 
TNFRSF11B, ADAMTS2,COL11A1,  
II Angiogenesis ;vasculature development, blood vessel development, 
blood vessel morphogenesis, angiogenesis 
5.15 ENG, ANGPT2, ANG2, TGFBR2, LEPR, 
PEG3, MP14,TNFRSF12A,TGFBR2, 
FGF2, ANXA2 
II Apoptosis ; apoptosis, programmed cell death, cell death, death 4.90 CASP2, TNFRSF11B, PEG10, NFKB1, 
PAWR, PDCD4, DAPK1, PDCD6IP, 
CFLAR, DAP3, ID1, BRE, SIVA1 
II Development; skeletal system development, bone development, 
ossification, osteoblast differentiation 
3.42 BMP4, SP7, BMP2, COL1A1, MMP14, 
BMP8A, IGF1, IGF2, IGFBP3, IGFBP5 
III Angiogenesis ;vasculature development, blood vessel development, 
blood vessel morphogenesis, angiogenesis 
 
3.97 FGFR1, TNFRSF12A, LEPR, CTGF, 
ANGPT2, EPAS1, ANG2, TGFBR2, 
ANXA2, TNFAIP2 
III Apoptosis ; apoptosis, programmed cell death, cell death, death 
 
3.31 TNFRSF21, TNFRSF11B, CASP2, 
CFLAR, GADD45G, PERP, PDCD6IP, 
HAND2 
III Embryonic development ; in utero embryonic development, chordate 
embryonic development, embryonic organ development 
 
2.93 SFRS1, APOB, PRMT1, CCNB2, FGFR1, 
RUNX1, COL2A1, NCOR2 
I,II, III Response to Reactive Oxygen Species ; response to ROS, response to 
oxidative stress, response to hydrogen peroxide 
 
2.86 CYP11A1,PRDX6,GPX3,MT1, 
PRDX2,COL1A1,PRNP,MT4 
I, II, III Extracellular Matrix ;collagen fibril organization, extracellular matrix 
organization, extracellular structure organization 
 
2.24 COL11A1,ADAMTS2,SERPINH1,COL5
A2,TNFRSF11B 
I, II, III Apoptosis ; cell death, apoptosis, programmed cell death, 
death 
 
2.13 CFLAR,TNFRSF21,TNFRSF1B,TNFRSF
11B,TNS1,HAND2,TNFAIP8, CASP2 
9
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Figure 3.3: Ingenuity pathways analysis  of dysregulated genes in classed BPH/5 
fetoplacental units compared to C57 controls.  (A-C) Top 15 functional pathways 
dysregulated in gene sets unique to Class I, II, and III respectively.  Numbers above 
bar graph indicate the number of genes dysregulated in that pathway. D) Network 
analysis showing Class I embryos have defects in cardiovascular system development 
and organismal development , (E) Class II fetoplacental units have dysregulation in 
cell death and embryonic development, (F) Class III fetoplacental units show 
dysregulation in cardiovascular system development and function, and cell cycle. 
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pathway as a whole and the numbers above the bar graph show the number of 
dysregulated genes within each pathway.    Additionally, network analysis reveals 
organismal development, cell death and embryonic development, and cell cycle 
defects in Class I, II and III respectively (Figure 3.3 D-F). 
 
Imprinted Genes are a subset of dysregulated genes in BPH/5.  Imprinted genes 
are known to be important in early mammalian development. Through the IPA and 
GO analysis, several imprinted genes emerged. We then sought to characterize these 
imprinted genes separately.  Figure 3.4 illustrates the six dysregulated imprinted genes 
in the BPH/5 fetoplacental units.  Four are paternally imprinted and two are 
maternally imprinted.  As paternally imprinted genes largely determine the placental 
size and morphology28, we hypothesized that these genes would be down-regulated in 
BPH/5 compared to C57. We validated the paternally imprinted genes by real-time 
PCR (Figure 3.4 panel A-D). True to our prediction, expression of all four paternally 
imprinted genes were significantly reduced in Class II and III compared to their 
healthier littermates (Class I), and/or C57 controls. 
 
DISCUSSION  
 Pre-eclampsia (PE), a pregnancy specific syndrome that affects approximately 
10% of pregnancies in the US each year, is characterized by late gestational 
hypertension and proteinuria (www.pre-eclampsia.org).  Early fetal loss complicates 
anywhere from 10-25% of clinically recognized pregnancies each year 
(www.americanpregnancy.com). BPH/5, an inbred mouse strain, exhibits the cardinal 
symptoms of PE during pregnancy, and loses a significant number of pups throughout 
gestation due to fetal loss 6, 7. This model provides a unique tool in examining how 
early pregnancy loss/distress may impact and play a role in the development of PE.    
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Figure 3.4: Imprinted genes are among the dysregulated genes in BPH/5 classed 
fetoplacental units. Table shows the imprinted genes that were dysregulated in our 
microarray analysis. Real time validation of paternally imprinted genes shows 
dysregulation in their expression in Class II and III embryos. Insulin-like growth 
factor 2 (Igf2, panel A), paternally expressed gene (Peg3, panel B), Slc38a4 (panel C) 
and delta-like 1 (Dlk-1, panel D) show a significant reduction in Class II and Class III 
embryos.  n=5-6 *p<0.05 vs C57 and † p<0.05 vs Class I.   
Imprinted 
Gene 
Function Maternal Paternal 
Igf2 Growth factor  X 
Peg 3 
Zinc finger transcription 
factor 
 X 
Slc38a4 Amino acid transporter  X 
Dlk-1 Function unknown  X 
Dcn Proteoglycan family X  
H19 Non-coding RNA X  
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Using ultrasound classification, we observed signs of fetal stress apparent at e10.5 in a 
subset of BPH/5 embryos. Using ultrasound to score these fetoplacental units, 
microarrays were run comparing the healthiest embryos with their more challenged 
littermates and also compared to the C57Bl/6 strain, which does not exhibit significant 
fetoplacental stress.  Pathways of angiogenesis, apoptosis and development were 
among pathways found to be highly dysregulated in fetoplacental units exhibiting 
developmental challenge in BPH/5.     
 Previous analysis of viable pups by necropsy revealed that fetal loss in BPH/5 
began at e12.5 where resorption sites were first visible 7. With the advances in high 
resolution imaging, such as ultra-high frequency ultrasound, structures as small as a 
murine embryo at e10.5 can be imaged with amazing clarity.  We have shown that 
evidence of fetal demise in BPH/5 can be traced earlier than necropsy data and 
demonstrate that one third of embryos show significant fetal developmental challenge 
or delay as early as e10.5.  From ultrasound data, we can classify embryos into three 
classes.  The healthiest embryos (Class I),  whose developmental status is closest to 
that of C57 controls, still show signs of IUGR, which has been previously documented 
in this model using neonatal weights7.  Class II embryos show severe developmental 
delay as well as placental pathology characterized by a poor development of the 
labyrinth and junctional zones.  Finally, Class III fetoplacental units show no evidence 
of placental or fetal development.  These classed samples, made possible by ultrahigh 
frequency ultrasound, provide an excellent starting material for molecular profiling of 
fetal challenge in this model of PE.     
 Microarray analysis is a powerful tool to investigate the etiology of disease.  In 
the past decade, over 20 researchers have used microarray technology to investigate 
the molecular profile of PE placentae in hopes of finding common mechanisms and 
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perhaps biomarkers.  These studies often do not reveal the same results as sample sizes 
are often very small due to the limitations of human placenta availability from both 
normal and pre-eclamptic patients11.  Also, it is becoming more widely recognized that 
the syndrome of PE can be subdivided into at least two separate pathologies, with an 
early onset and  late onset classification, each with a unique profile and set of 
complications1, 10, 29.    It is also known that the pathogenesis of pre-eclampsia begins 
long before the onset of maternal symptoms5. As such human placental samples 
available from term biopsies provide only the end results of PE and do not shed light 
on the early events at the onset of disease. 
 In this study, microarray analysis was used to determine the gene expression 
profile in fetoplacental units of varying status in the BPH/5 mouse model. Class I 
fetoplacental units, though they are the healthiest, still show dysregulation in genes 
involved in extracellular matrix remodeling and cell adhesion. These targets are most 
likely involved in the invasion and remodeling of the maternal uterine environment. 
Interestingly, targets found in this study such as COL5A2, COL1A1, ADAMTS2 were 
also found in a study linking fetal connective tissue defects to preterm birth30.  Many 
of these may be targets that lead to shallow placental invasion into the decidua and 
reduced labyrinth formation characteristic of this model6. Class II fetoplacental units 
show dysregulation in genes involved in embryo development (predominantly bone), 
angiogenesis and apoptosis. Angiogenic factors have received much interest in the 
past few decades as both a mechanism behind placental pathologies such as reduced 
spiral artery remodeling in PE patients31, and reduced levels have also been examined 
as a potential screening biomarker of women who go on to develop PE32.  Previous 
work in our laboratory has shown a decrease in angiogenic potential that is present 
prior to the development of the PE symptoms in BPH/5 mice33, and that increasing 
circulating levels of the angiogenic factor VEGF resolves many of the symptoms of 
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PE. Additionally, the area of bone development, a process very sensitive to circulating 
angiogenic levels, has significant dysregulation in Class I and II fetoplacental units, 
confirming the effects of our previous findings.   Genes involved in apoptosis are also 
dysregulated in Class II and III embryos as they are probably so challenged that they 
are likely in the cohort that perish.  Finally, Class III embryos again show defects in 
angiogenesis and apoptosis as well as embryo development. This is not surprising 
given the profound defects in both embryo and placental development common in this 
class of fetoplacental units.  Several microarray studies have examined the role of 
hypoxia in gene regulation in the PE placenta10, 11, 17, 34, 35. The response to reactive 
oxygen species is a functional group that is highlighted in genes that are dysregulated 
in all classes of BPH/5 fetoplacental units, again highlighting the role of hypoxia in 
this model as it parallels the human studies.  Our group has examined the role of 
reactive oxygen species and showed that the antioxidant Tempol ameliorated many of 
the PE symptoms in BPH/5 mice36.  
 From our microarray work, we found several imprinted genes to be 
dysregulated in classed fetoplacental units of BPH/5. Imprinted genes are very 
important in early mammalian development, and are abundantly expressed in the 
placenta37-39.  The Kinship theory states that paternally imprinted genes classically 
govern the size of the placenta in order to maximize the maternal resources acquired 
for the growing fetus, while the maternal imprinted genes generally conserve maternal 
resources for all of her current litter as well as future litters28.  Studies reviewed by 
Angolioni and colleagues and Tycko and Morison, summarize the fetal and placental 
data acquired from several mouse knockout models28, 38. These knockout mouse 
models show drastic defects in placental anatomy and size or fetal size, depending on 
if a maternal or paternal gene is silenced.  Additionally, recent studies have examined 
the role of imprinted genes and have found a significant correlation with altered 
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expression of imprinted genes in response to maternal underperfusion, a common 
phenotype of both IUGR and pre-eclampsia40.  These include PLAGL1, PHLDA2, 
MEST, MEG3, LEP and IGF1.  Interestingly, some linkage studies show the 
involvement of maternally expressed genes in some families with the occurrence of 
pre-eclampsia41.  We hypothesized, given the placental defects in BPH/5, that paternal 
imprinted genes would be down-regulated, given their importance in placental 
development. Indeed several paternal genes, many of which have knockout models 
known, were downregulated in BPH/5 including Dlk-1, Igf2, Peg3 and the amino acid 
transporter Slc38a4. Knockout models of these genes show the phenotype of 
abnormally large fetuses, and small placentae, indicative of the loss of the paternally 
imprinted stiumulus.  Additionally the maternally imprinted genes decorin and H19 
were also dysregulated in our model.   Decorin, a proteoglycan, was highly 
upregulated in all of our classes (data not shown). Recently several studies indicate 
increased decorin expression in the umbilical vessels in pregnancies complicated with 
pre-eclampsia and have been speculated to alter the mechanics of fetal circulation42. 
Future studies to examine the methylation status of our imprinted genes in this model 
as well as spatiotemporal expression of these genes throughout the early gestation 
period would be helpful in characterizing how these genes affect placental 
development. 
 Using ultrasound-mediated scoring of implantation sites, we have identified 
numerous dysregulated pathways that shed light on the causes of fetal demise in our 
mouse model. It is interesting to speculate how these dysregulated pathways in healthy 
and compromised embryos contribute to the pathophysiology of PE in this model.  
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CHAPTER FOUR:  
PERI-IMPLANTATION DEFECTS AND ASYNCHRONOUS MATERNAL-
FETAL INTERACTIONS IN A MURINE MODEL OF PRE-ECLAMPSIA, 
BPH/5  
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SUMMARY 
BPH/5 mice develop the hallmarks of pre-eclampsia (PE), accompanied by placental 
defects and reduced litter sizes due to progressive fetal loss during gestation. We 
examined the peri-implantation period to see if placental defects could be traced to a 
defect at this time. We observed a significant delay in blastocyst development in 
BPH/5 compared to controls. We then hypothesized that this blastocyst delay in 
BPH/5 would impact implantation. Pontamine blue perfusions revealed a significant 
delay in implantation in BPH/5 vs C57Bl/6 controls, with a reduction in the number of 
implantation sites present at the beginning of the implantation window. Interestingly, 
later implanting embryos contribute to a clustering defect in BPH/5. Whereas C57 
embryos were evenly spaced along the uterine horns, BPH/5 embryos were often 
crowded/clustered. To examine maternal-fetal interactions during implantation, 
reciprocal embryo transfers were used. Interestingly, clustering was only observed 
when BPH/5 embryos were placed in BPH/5 recipients.  We next characterized the 
maternal endocrine profile and showed premature estrogen and progesterone signaling 
in BPH/5. To coordinate implantation events in BPH/5 the delayed implantation 
model was used.  Using this model, embryo clustering was nearly completely resolved 
in BPH/5, suggesting a link between embryo maturation and maternal endocrine 
signaling and implantation defects observed in BPH/5.  Additionally, synchronizing 
implantation had significant effects on placentation in this model.  In summary, BPH/5 
exhibit marked abnormalities in early gestational processes. 
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INTRODUCTION 
 The initiation of pregnancy and the implantation process is a highly intricate 
and coordinated set of maternal and fetal events.  For implantation to occur, the uterus 
must be in a receptive phase, governed by the endocrine signaling of ovarian steroids 
estrogen and progesterone 1-3.  This timeframe has been coined the “window of 
receptivity.”  Additionally, the embryo must have reached the blastocyst stage and be 
activated for the crosstalk between the mature blastocyst and luminal epithelium of the 
uterus to occur 1, 4.  Several key growth factors, cytokines, homeotic genes, vasoactive 
factors and developmental genes are involved in the processes of embryo-uterine 
apposition, implantation and the initiation of the decidualization process (reviewed in 
Dey, 20042). Although significant progress has been made toward understanding these 
early processes, further studies are needed to improve problems of infertility, 
pregnancy initiation and pregnancy loss. 
 The precise synchronization of embryo readiness and the “window of 
receptivity” is critical in pregnancy success and fetal heath.   Wilcox and colleagues 
examined the rate of pregnancy success and the timing of implantation in the ”window 
of implantation” and found an exponential increase in fetal loss when embryos implant 
even 24 hours outside the optimal implantation window 5.  This has significant 
repercussions for both naturally conceived pregnancies and many of the pregnancies 
that make use of assisted reproductive technologies (ART).   ART pregnancies, 
specifically in vitro fertilization (IVF), involve coordinating the events from 
fertilization through to implantation artificially. As such, synchronization is key to the 
success of these pregnancies.   Pregnancies initiated by ART require close monitoring 
as these pregnancies are often high risk, with increased rates of adverse maternal, fetal 
and placental outcomes.  Historically, these complications were thought to be linked to 
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the increased rate of multiple pregnancies in ART 6, though the trends are holding true 
for singleton pregnancies as well7. Many pregnancies initiated by IVF show increased 
risk of preterm birth, low birth-weight fetuses, as well as increased placental 
abruption, placenta previa and an increased risk of pre-eclampsia    ( PE)7-9.  As these 
pregnancies are initiated and implantation is coordinated artificially, these outcomes 
highlight the importance of the peri-implantation period in successful pregnancy 
outcomes. 
 One of the pregnancy outcomes that that is significantly increased in IVF 
pregnancies is the incidence of PE .   PE is a pregnancy associated disorder that affects 
approximately 10% of pregnancies and is the leading cause of fetal and maternal 
deaths worldwide 10, 11. It is characterized by new onset hypertension and proteinuria 
present during the third trimester.   It has long been known as a disease that is closely 
tied to the placenta since.   The symptoms resolve when the fetus, and more 
importantly, the placenta, are delivered.  In addition, molar pregnancies, where the 
placenta is present but an embryo is absent, have been associated with PE, which links 
this organ to the etiology of the syndrome12, 13. Many of the placental defects present in 
PE pregnancies include shallow placental invasion and reduced spiral artery 
remodeling10, both of which are linked to defects in cells from a single lineage, the 
trophoblast cells14, 15. As such, it has been argued that defects in placentation can be 
traced back to the establishment and activation of this important cell type. This sets the 
initiation of this pathological cascade to the peri-implantation period, a time frame far 
earlier than had been previously considered16.    
 Studying a disease of human placentation such as PE is very difficult without 
the use of animal models. This is particularly true now as the focus of 
pathophysiological hypotheses is moving earlier and earlier to the peri-implantation 
period16, when biomarkers and placental specimens are unattainable in human 
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pregnancies.  BPH/5 is an inbred mouse strain that spontaneously exhibits the cardinal 
symptoms of PE during pregnancy 17. This strain also has many of the placental 
phenotypes associated with the human disease, including reduced spiral artery 
remodeling and shallow trophoblast invasion18, which begins before onset of maternal 
symptoms.  Additionally, fetal demise and small pups also characterize this strain17, 18.  
As this model recapitulates many features of the human disease, including poor 
fetoplacental outcomes, BPH/5 mice provide a unique opportunity to examine the role 
of the peri-implantation period.  We hypothesize that there are significant defects 
within the peri-implantation period, and that some of these defects may be causally 
linked to the placental defects observed in this model.  
 
METHODS 
Animals and Husbandry.  Experiments were performed in 8-12 wk old BPH/5 and 
control C57Bl/6 (C57), 129, Balb/c, BPH/2 and BPN/3 mice obtained from in-house 
colonies. Animals were housed and maintained as previously described17.   BPH/5 is 
an inbred strain derived from the spontaneously hypertensive BPH/2 strain, which was 
originally established through an eight-way cross that included C57Bl/6, 129 and 
Balb/c17, 19.   Mice underwent strain-matched mating and presence of a vaginal plug in 
the morning was defined as gestational day e0.517. All animal procedures were 
approved by the Institutional Animal Care and Use Committees at Cornell University, 
and are in accordance with the PHS Guide for the Care and Use of Laboratory 
Animals, USDA regulations and the AUMA panel on Euthanasia. 
 
Early embryo isolation and culture.   Embryos from e3.5 pregnant mice were flushed 
from the uterus in specialized media containing IMDM (Gibco),15% FBS, non-
essential amino acids, β-mercaptoethanol, glutamine and penicillin-streptomycin. 
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Embryos were staged and then cultured individually in 48 well plates using complete 
media containing DMEM (Gibco), 15% FBS, non-essential amino acids, sodium 
pyruvate, penicillin-streptomycin and β-mercaptoethanol.  Embryos were 
photographed and staged for 5 days. Embryos were classified as morula, blastocyst, 
hatched, plated (outgrowth present on the bottom of the dish), or dead. 
 
Oocyte isolation and culture.  Fertilized oocytes were collected from the oviduct from 
e0.5 pregnant mice. Eggs were dissociated from cumulus cells using standard 
hyaluronidase enzyme digestion (Sigma). Oocytes cultured individually in KSOM 
media (Millipore) for 5 days. Embryos were photographed and staged daily. Embryos 
were classified as fertilized, 2cell, 4cell, morula, blastocyst, or dead. 
 
Pontamine blue perfusion.  A single injection of 100μl of 0.1% pontamine blue 
(BDH) dissolved in saline was administered via tail vein injection into pregnant mice  
at e5.5 or where otherwise noted. After ten minutes, mice were euthanized via CO2 
asphyxiation and the uterus was dissected, fixed in 4% paraformaldehyde for 24 hours, 
and photographed. Clusters were defined as embryos that were spaced less than one 
embryo width apart from each other.  For time course experiments, pontamine blue 
perfusions were carried out at 0 00h e4.5, 7 00h e4.5, 19 00h e4.5 and 10 00h e5.5.    
 
Histology and morphometric analyses.   Whole implantation sites including embryos 
at e5.5 were excised, fixed in 10% neutral buffered formalin, and embedded in 
paraffin using standard procedures.  The entire implantation site was serially sectioned 
at 5μm, mounted on slides, and stained with H&E using standard protocols. Analyses 
were carried out on the sections in which the embryo area was greatest.  Quantification 
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of the area of the embryo, the area of decidualization, and the length of the embryo to 
the antimesometrial pole was measured using Image J software (version 1.33, NIH). 
 Additional morphometric analyses were carried out on e12.5 fetoplacental 
units. Samples were isolated and processed as stated above. Sections were stained 
using isolectin B4 staining as previously described 18. Implantation depth was analyzed 
using Image J software (version 1.33, NIH) as previously described 18.  
 
Embryo transfer studies. Embryo transfer experiments were carried out using 
standard procedures. Donor female mice from C57 and BPH/5 strains were mated and 
embryos were isolated at e3.5 as above. Alongside donor mice, recipient mice were 
mated with vasectomized males to initiated pseudopregnancy.  Recipient females were 
anaesthetized at e2.5 using ketamine (100mg/kg) and xylazine (10mg/kg) and two 
small dorsal incisions were made to exteriorize the distal uterine horns.  Eight to ten 
donor embryos were injected per uterine horn. Mice were allowed to recover and 
pontamine blue studies were carried out as above at e5.5 of pseudopregnancy. 
 
Blood collection and endocrine assays. Blood was collected for endocrine measures 
via cardiac puncture at 7 00h and 19 00h for a time course beginning at e1.5 at 19 00h 
through e4.5 at 7 00h.  Blood was left at room temperature to clot for 90 minutes prior 
to centrifugation at 3500 RPM for 20 minutes.  Serum was immediately frozen at        
-80ºC. An estrogen ELISA (Calbiotech) was performed according to manufacturer‟s 
instructions.  The sensitivity of this assay is 3pg/mL.   Progesterone levels were 
measured by RIA at the Ligand Assay and Analysis Core Laboratory at the University 
of Virginia.  The sensitivity of this assay is 0.05ng/mL  
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Delayed implantation studies.   Ovariectomies were performed on the afternoon of 
e2.5 in pregnant C57 and BPH/5 mice.  Mice were anaesthetized with ketamine 
(100mg/kg) and xylazine (10mg/kg) and dorsal incisions were made to exteriorize and 
remove the ovaries.  After recovery, mice received daily subcutaneous injections of 
progesterone (P4) (Watson) at a dose of 1mg/mouse.  To initiate implantation, 
estrogen (25ng/mouse, Sigma) was injected subcutaneously. Mice then received daily 
progesterone injections until the time of sample collection.  All hormones were 
dissolved in sesame oil (Sigma).   
Quantitative Real time PCR.  Entire implantation sites, including uterine tissue and 
embryo, were dissected from clustered and spaced embryos from BPH/5 and C57 
samples at e5.5, or the equivalent gestation day for delayed implantation mice.  RNA 
was extracted using a standard Trizol method and total RNA content quantified by 
spectrophotometry.  Several candidate genes were assayed based on their importance 
in developmental processes. For a complete list of target genes and primers, see Table 
4.1. Quantitation of gene expression levels were performed by amplification of cDNA 
(equivalent to 25 ng input RNA) using SYBR Green (Quanta) and primers specific to 
each gene.  Primers were designed and validated using Primer Quest software (IDT).     
All primers were purchased from integrated DNA technologies (IDT) (see Table 4.1 
for primer sequences). Samples were subjected to forty cycles of PCR (50 , 2 min; 
95 , 10 min; 40X [95 , 0:15 min; 60 , 1 min]) followed by a dissociation protocol.  
Each sample was run in duplicate and gene expression was analyzed using the ddCt 
method.  mRNA levels were normalized to β-actin (to generate dCt) and compared to 
respective C57 controls, either by natural mating or delayed implantation model (to 
generate ddCt).  Sequence-specific amplification was confirmed by a single peak 
during the dissociation protocol following amplification.  
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Ultrasound assessment of fetal health.  Pregnant mice at e12.5 were anaesthetized 
using 2%isofluorane. The Vevo 770 ultrahigh frequency ultrasound was used to 
examine fetal health (Visualsonics).  A ventral incision was made to exteriorize the 
uterus and examine individual implantation sites using a 40MHz probe. Body 
temperature of the pregnant females was maintained and monitored throughout the 
recording procedure. Fetal heart rates were measured and reported as a ratio of fetal 
heart rate to maternal heart rate to control for minor variations in anesthetic efficacy.  
Umbilical blood flow was measured using Doppler measurements of the umbilical 
vessels.  After recording, the pregnant mice were euthanized via cervical dislocation 
and implantation sites were dissected and fixed for histological examination as stated 
above. 
 
Statistical Analyses. All data are expressed as mean ± SEM ANOVA followed by 
Newman-Keuls test for significance was performed for all data sets. p<0.05 was 
considered statistically significant. 
RESULTS 
BPH/5 embryo show marked pre-implantation embryo maturation delay. 
Previous studies in the BPH/5 mice show marked placental defects and evidence of 
fetal demise starting as early as e9.5 of gestation 18 (also Chapter 3).  We postulated 
that these abnormalities could have their origin in the peri-implantation period. We 
first sought to examine the pre-implantation embryos from both mouse strains.   
Whereas C57 control embryos flushed from the uterus at e3.5 (referred to as Day 1) 
were at the expected blastocyst stage 20, embryos isolated from BPH/5 mice at this 
time point were predominantly at the morula stage or younger (see Figure 4.1A for 
C57 and B for BPH/5). On Day 1, approximately 85% of embryos in C57 were in the  
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Table 4.1: Primer sequences for genes in early developmental processes. 
Gene Peri-Implantation Function Primer Sequence 
Areg Growth factor in uterine 
epithelium 
5‟ TCT GCC ATC ATC CTC GCA GCT ATT 3‟ 
5‟CGG TGT GGC  TTG GCA ATG ATT CAA 3‟ 
Bmp2 Developmental gene involved in 
decidualization 
5‟TGT GGG CCC TCA TAA AGA AGC AGA 3‟ 
5‟AGC AAG CTG ACAGGT CAG AGA ACA 3‟ 
CB1 GPCR on blastocyst surface 5‟CCA CTG TGC AGT  TGC TGT TTC CTT 3‟ 
5‟ TTG GCC ATC GAG GCC TGA AAT CTA 3‟ 
c-Myc Gene highly expressed in 
activated blastocysts 
5‟ ACT TAC AAT CTG CGA GCC AGG ACA 3‟ 
5‟ GCC CAA AGG AAA TCC AGC CTT CAA 3‟ 
Cyclin B Cell cycle mediator in 
maintenance of mitotic cell cycle 
5‟TGT GTG TGA ACC AGA GGT GGA ACT 3‟ 
5‟ AGA TGT TTC CAT CGG GCT  TGG AGA3‟ 
Cyclin D3 Cell cycle mediator in 
decidualizing stromal cells 
5‟AAA CAG ATG TCC TGC AGC GAG AGA3‟ 
5‟ TTC TGG AAG GTC TTG CTG GTC CAT 3‟ 
Fkbp52 Immunophilin in uterine stroma 5‟AGC TGG AGC AGA GCA ACA TAG TGA3‟ 
5‟TCA GGT GAC ACA TGG CCA GAT TGA 3‟ 
Hegfl Growth factor in early 
recognition of uterus to attaching 
blastocyst 
5‟TTA TCC TGC TGT TCT TCG GGT GCT 3‟ 
5‟ TCA ACT CCA AAG CTC CCT GCT CTT 3‟ 
Hoxa-10 Transcription factor in uterine 
stroma 
5‟TTA GCT AAA GGG CTT GAC CTG GCT 3‟ 
5‟AGA GAG GTT TCC TTC TCT TGC CCA 3‟ 
Lif Cytokine in uterine glands and 
stroma surrounding implanting 
blastocyst 
5‟TCA GCG ACA AAG TTA CTC CAC CGT 3‟ 
5‟AAG TGA TGA CAA AGC CCA ACA GGC3‟ 
Ptgs1 Murine Cox1, vasoactive factor 
in luminal epithelium and glands 
of uterus 
5‟CTT TGC ACA ACA CTT CAC CCA CCA 3‟ 
5‟TTG AAG AGC CGC AGG TGA TAC TGT 3‟ 
Ptgs2 Murine Cox2, vasoactive factor 
in luminal epithelium of uterus 
5‟ACT GGG CCA TGG AGT GGA CTT AAA 3‟ 
5‟AAC TGC AGG TTC TCA GGG ATG TGA 3‟ 
Wnt3a Developmental gene activated 
during blastocyst maturity 
5‟ATG CCT CAG AGA TGT TGC CTC ACT 3‟ 
5‟ TCA GAT GGG TCC TGA AAC AAC CCT 3‟ 
Wnt4 Developmental gene involved in 
decidualization 
5‟GCA GAT GTG CAA ACG GAA CCT TGA 3‟ 
5‟ACA CCT GCT GAA GAG ATG GCG TAT 3‟ 
β-actin Housekeeping gene 5‟ CAT CCT CTT CCT CCC TGG AGA AGA 3' 
5‟ACA GGA TTC CAT ACC CAA GAA GGA 
AGG3‟ 
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Figure 4.1: BPH/5 embryos show delayed pre-implantation and slowed in vitro 
embryo maturation kinetics compared to related strains.  Summary of percentages 
of embryos at various stages when cultured in vitro for 5 days after e3.5 isolation. C57 
(A) and BPH/5 (B) are shown along with related parental strains 129 (C), Balb/c (D), 
BPH/2 (E), and BPN/3 (F). n=5-7 litters per strain.  *p<0.05 vs C57 stage- and day-
matched control. 
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blastocyst stage, where inner cell mass and trophoblast lineages are first segregated. 
This is in contrast to Day 1 of BPH/5 isolation, were 82% of embryos were still in the 
morula stage, where cells destined for trophoblast and inner cell mass fates have not 
segregated.  To determine the maturation kinetics of these strains, we cultured these 
embryos in vitro for five days.  By the second day in culture, 66% C57 embryos had 
begun to hatch while the BPH/5 population was only just reaching the blastocyst 
stage.  This significant delay in BPH/5 embryo maturation continued throughout the 
culturing period, with the BPH/5 embryos showing a ~24 hour delay compared to their 
C57 counterparts. In order to rule out simple strain differences, BPH/5 parental strains 
129 and Balb/c were characterized as these strains were part of the original 8-way 
cross in establishing the BPH sublines17, 19.  We also examined the closely related 
BPH/2 (the high blood pressure related strain from which BPH/5 was derived as a 
subline) and BPN/3 (normotensive subline from the original 8way cross) strains 
(Figure 4.1 C-F, respectively)19.  Interestingly, while Balb/c and BPH/2 strains showed 
a significant morula population the first day of isolation (Figure 4.1D and E), the 
kinetics soon resolved to mature at a rate similar to C57 controls. BPH/5 was the only 
strain to show such a sustained and significant delay. 
 
BPH/5 embryos do not show maturation defect at the fertilization step.  As a 
significant delay was found in embryos isolated at e3.5, we wanted to rule out a 
deficiency in oocyte integrity.  A similar strategy was adopted as the previous studies, 
where fertilized oocytes were isolated from the oviduct at e0.5 and cultured in vitro for 
five days. There were no differences in the number of oocytes ovulated between 
BPH/5 and C57 control mice (Figure 4.2 A). Furthermore, there was no significant 
difference in the progression from fertilized oocyte to the two- cell stage between the 
strains (Figure 4.2B and C), with only 20% of BPH/5 oocytes remaining in the single  
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Figure 4.2: BPH/5 fertilized embryos progress to the 2 cell stage at a similar rate 
to C57 controls. Summary of number of fertilized oocytes isolated from each strain 
(A). Summary of staged fertilized embryos from C57 (B) and BPH/5 (C) cultured in 
vitro for 5 days post e0.5 isolation. n=4-5 litters per strain*p<0.05 vs C57 stage- and 
day-matched control.  
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cell stage on Day 2.  The more marked embryo maturation delay in BPH/5 seems to 
originate in the progression from the 4 to 8-cell stage.  This is where the BPH/5 delay 
starts and leads to differences observed in Figure 4.1.  
 
 BPH/5 exhibit embryo clustering.  We have demonstrated in the above data sets 
significant pre-implantation maturation delay in BPH/5 embryos compared to C57 
controls. We hypothesized that these pre-implantation defects may translate to defects 
in the implantation process in vivo.  To test this, we examined implantation sites at 
e5.5 using the pontamine blue perfusion method.  This method allows for the detection 
of early implantation sites along the uterine horn where the uterine decidualization 
reaction causes the blue dye to be trapped in the tissue, facilitating imaging and 
quantification of these sites. Figure 4.3A and B show representative photomicrographs 
of uteri from C57 and BPH/5 mice, respectively.  C57 show even spacing between 
embryos along both uterine horns, which is consistent with what has been reported 
previously for this strain 21. In contrast, BPH/5 show a marked implantation site 
spacing defect (Figure 4.3B and inset).  Although the number of implantation sites is 
similar between the strains (Figure 4.3C),  summary data presented in Figure 4.3D 
reveal that BPH/5 embryos implant in a clustered arrangement nearly 40% of the time. 
Embryo clustering is extremely rare in C57 controls (Figure 4.3D).   
As we established a significant delay in BPH/5 embryo maturation in vitro 
(Figure 4.1), we decided to perform a more detailed examination of the window of 
implantation kinetics in vivo by performing a time-course beginning at e3.5 midnight 
through to the morning of e5.5.  As seen in Figure 4.3E, BPH/5 showed a significant 
reduction in the number of implantation sites present at the beginning of the window  
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Figure 4.3: BPH/5 exhibit increased clustering/crowding of implantation sites. 
Representative Pontamine blue stained uteri of C57 (A) and BPH/5 (B) with inset at 
higher magnification and arrows indicating implantation sites. Summary showing the 
total number of implantation sites (C), and the percentage of embryos observed in a 
cluster at e5.5 (D).  Summary of the implantation time-course reflecting the number of 
implantation sites (E) and the percentage of embryos in a cluster (F) during several 
stages within the window of implantation. Summary data of the percentage of embryos 
in a cluster across closely strains closely related to BPH/5, BPH/2 and BPN/3 (G). 
n=5-6, *p<0.05 vs C57. 
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of implantation (Figure 4.3E). This delay is resolved by the beginning e4.5am 
measurement, and both strains‟ implantation rates remain similar through to the end of 
the implantation window. Interestingly, the embryos that implant later during the 
implantation window are more likely to be in a cluster (Figure 4.3F).  Pontamine blue 
perfusions were also carried out in the closely related BPN/3 and BPH/2 strains, where 
no clustering of implantation sites was observed (Figure 4.3G), again suggesting that 
these peri-implantation defects are unique to BPH/5. 
 
Morphometric analysis reveals abnormalities in implantation sites of BPH/5 
mice.  We next examined BPH/5 implantation sites using histology. Serial sectioning 
of e5.5 implantation sites from both clusters and normally spaced embryos revealed 
significant morphometric abnormalities. First, BPH/5 implantation sites show the 
presence of a persistent lumen (Figure 4.4A) along the mesometrial pole of the 
implantation sites.  This characteristic is common to all BPH/5 implantation sites, 
regardless of embryo spacing.   The quantification of implantation site sections show 
decreased area of decidualization surrounding the embryo and a smaller embryo in 
BPH/5 implantation sites compared to C57 (Figure 4.4B and C respectively).   This 
was observed in both clustered and normally spaced BPH/5 implantation sites.  We 
next examined the spacing of embryos to the antimesometrial pole to examine the 
depth of implantation. BPH/5 embryos that are spaced normally and C57 embryos 
implant to the same depth, where as clustered embryos show a more shallow invasion 
(Figure 4.4D). 
 
Implantation defects in BPH/5 require both an embryonic and maternal 
contribution.  As implantation requires synchronization of maternal and embryonic 
contributions, we decided to dissect the maternal and embryo components using an  
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Figure 4.4: BPH/5 implantation sites at e5.5 show significant morphometric 
defects. Representative cross section of BPH/5 implantation sites stained with H&E 
(A). Summary of the surface area of decidualization surrounding the embryo (B), the 
surface area of the embryo (C) and the distance from the embryo to the 
antimesometrial pole (D) in C57 implantation sites, BPH/5 individually spaced 
implantation sites as well as BPH/5 embryos in a cluster. n=4-6, *p<0.05 vs C57, 
#p<0.05 vs BPH/5 spaced embryos. AM-antimesometrial pole, L=lumen, E=embryo, 
DE=decidua 
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embryo transfer strategy.  We performed a series of transfers where separate pools of 
embryos from either BPH/5 or C57 strains were implanted along separate uterine 
horns within the same pseudopregnant recipients. This allowed us to examine the 
effect of the embryo maturation on implantation.  By having both strains within the 
same recipient we were able to control for the maternal uterine environment.  If 
clustering is an embryo-driven phenotype, then any recipient receiving BPH/5embryos 
would not space them evenly. If clustering is a defect in the maternal uterine 
environment, BPH/5 mothers would not be able to space embryos, independent of 
strain origin and maturation state.  Schematic representation of the results is shown in 
Figure 4.5A, where clustering was observed only when BPH/5 embryos were 
transferred into BPH/5 uteri.  Figure 4.5B shows a summary of the percentage of 
clustered embryos present in all the respective crosses.  BPH/5 embryos in BPH/5 
mothers were the only combinations where clustering was observed, implicating both 
a maternal and embryo contribution to implantation defects. 
 
Examination of the maternal endocrine contribution shows premature signaling 
for implantation.  Embryo transfer experiments implicate the maternal component, at 
least in part, in the embryo spacing defect observed in BPH/5. Since the maternal 
endocrine profile determines the period of uterine receptivity 20, we decided to 
examine the maternal endocrine signaling surrounding the implantation period. Serum 
was collected at 700h and 1900h beginning at e1.5 through e4.5.  Estrogen levels were 
measured by ELISA and show a significant shift in BPH/5 estrogen signaling.  The 
estrogen surge is earlier in BPH/5 mice compared to C57 controls, with a significant 
increase in this hormone at e2.5am then returning to baseline at e2.5pm. This is in 
contrast to C57 estrogen surge which begins at e2.5pm and does not return to baseline 
until e3.5pm (Figure 4.6A).   Progesterone measured by RIA reveals a marked  
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Figure 4.5: Clustering defects are only present when BPH/5 mothers carry BPH/5 
embryos.  Schematic representation of the results of embryo transfer experiments 
illustrating the occurrence of clustering when C57 or BPH/5 embryos were placed in 
C57 or BPH/5 recipients (A). Summary of the percentage of clustered embryos at e5.5 
with all embryo transfer experiments is shown in (B). n=4 embryo transfers/recipient 
strain. *p<0.05 vs C57 to C57 cross. 
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Figure 4.6: BPH/5 endocrine signaling shifts the window of implantation early in 
this strain compared to C57 controls. Summary of estrogen (A) and progesterone 
(B) levels determined over the timecourse indicated. n=4-10, *p<0.05 vs time matched 
C57 controls, # p<0.05 vs strain matched baseline levels. 
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increase in progesterone levels in BPH/5 by e2.5 (Figure 4.6B) that resolves by e3.5 
1900h.  This combined hormone profile reveals a premature endocrine surge in BPH/5 
compared to C57 controls. 
 
Artificially synchronizing maternal uterine receptivity and embryo maturation 
resolves implantation defects in BPH/5. Our studies have demonstrated both a 
delay in embryo maturation and premature maternal hormonal signaling. To determine 
if there is a functional link between these asynchronous events and implantation 
defects in BPH/5, we made use of the delayed implantation model. This procedure 
allows for the elongation of the window of receptivity through exogenous 
progesterone hormone supplementation and for implantation to be elicited in a 
coordinated fashion through a single estrogen injection22.   Importantly, this procedure 
had no effect on implantation success in either BPH/5 or C57 mice (Figure 4.7A). 
Interestingly, there was a significant reduction in the BPH/5 clustering defect when 
peri-implantation events are synchronized (Figure 4.7B).   
 
Genes in early development are dysregulated in natural BPH/5 pregnancies but 
are rescued in delayed implantation BPH/5 mice.  To examine the molecular profile 
and potentially determine the mechanism of implantation defects in BPH/5, we 
performed real-time PCR to examine the expression of  several candidate genes 
known to be involved in early developmental processes (see Table 4.1).  We 
performed these studies using implantation sites from both natural pregnancies and 
synchronized pregnancies.  Many of the dysregulated genes in the natural BPH/5 
implantation sites include genes directly linked to endocrine signaling (Areg, Fkbp52 
and Lif; Figure 4.8A, B, C respectively) or downstream of initial endocrine signaling 
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Figure 4.7: Artificially synchronizing embryo maturation with uterine receptivity 
resolves implantation defects.  Summary of the number of implantation sites from 
mice receiving an ovariectomy (ov) and daily hormone supplementation compared to 
natural matings (A). Summary data of the percentage of clustered embryos in naturally 
mated C57 and BPH/5 compared to strain matched pregnancies that received an 
ovariectomy (B). n=5-6, *p<0.05 vs respective C57 controls. 
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Figure 4.8:  Synchronizing embryo maturation and uterine receptivity resolves 
molecular defects in implantation sites. Summary of mRNA levels of Areg  (A), 
Fkbp52 (B), Lif (C) and Ptgs2 (D) in natural pregnancies of BPH/5 clustered and 
spaced embryos as well as BPH/5 implantation sites from artificially synchronized 
pregnancies.  n=5-6, *p<0.05 vs respective C57 controls. 
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(Ptgs2; Figure 4.8D).  Progesterone sensitive targets Areg and Fkbp52 were 
significantly elevated in both spaced and clustered implantation sites from natural 
pregnancies compared to control C57s (Figure 4.8 A-B).  Estrogen sensitive Lif 
showed a decrease in gene expression in natural BPH/5 implantation sites, both spaced 
and clustered (Figure 4.8C). Finally, Ptgs2 showed a significant increase in transcript 
levels in BPH/5 implantation compared to C57 controls (Figure 4.8D).  As with 
morphometric analyses, individually spaced embryos and clusters were 
indistinguishable in their molecular profile.  Interestingly, by synchronizing 
implantation events, all of these molecular differences in natural BPH/5 implantation 
sites were resolved to control C57 levels (Figure 4.8 A-D). 
 
Synchronization of implantation events has beneficial effects on placentation in 
BPH/5.   As we have demonstrated significant improvement in spacing defects and 
candidate gene expression when maternal and embryo components are synchronized, 
we decided to continue some of these pregnancies to e12.5 to examine the effects of 
synchronization on fetoplacental outcomes.  We began by examining fetal health in 
these synchronized embryos using ultra-high frequency ultrasound (see Chapter 3). As 
shown in Chapter 3, fetal heart rates, expressed as a ratio to maternal heart rate, were 
were significantly lower in BPH/5 than in C57 controls, and synchronization of 
implantation events had no effect on this developmental defect (Figure 4.9A). 
However, umbilical blood flow was significantly altered by synchronization. As seen 
in Figure 4.9B, BPH/5 embryos from natural pregnancies showed diminished 
umbilical blood flow compared to C57 controls.  Synchronizing implantation events 
significantly improved this parameter in BPH/5 such that umbilical blood flow was 
now similar to that observed in C57 controls (Figure 4.9B).   Importantly, the artificial  
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Figure 4.9: Rescuing implantation processes improves placental defects in BPH/5. 
Summary of fetal heart rates (expressed as a ratio of fetal to maternal heart rate) (A) 
and umbilical blood flow (B) gathered from ultrasound measurements of embryos at 
e12.5 of naturally mated and ovariectomized (ov) BPH/5 and C57.   Representative 
images of isolectin stained C57 (C) BPH/5 natural (D) and implantation synchronized  
mice. (E) Summary data of quantification of placental depth (F). n=4-6,or where 
indicated,  p<0.05 vs C57 controls, #p<0.05 vs BPH/5 natural mating. P=placenta, 
De=decidua 
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synchronization procedure had no effect on fetal heart rates or umbilical blood flow in 
C57.  
BPH/5 mice have well characterized placental defects, including shallow 
invasion of the trophoblast into the maternal decidua 18.  We next examined whether 
synchronization altered this endpoint in BPH/5. Isolectin stained sections showed 
shallow expansion into the maternal decidua in natural BPH/5 placentae (Figure 4.9D) 
compared to C57 controls (Figure 4.9C), consistent with previous findings18.  This was 
measured by comparing the length of the labyrinth and junctional zones in relation to 
the depth of the placenta and decidua as a whole as described18.  Interestingly, 
placentae from pregnancies where implantation events were synchronized showed 
increased placental expansion and labyrinth development (Figure 4.9E). The ratios of 
the fetoplacental components to the depth of the whole placental disk are quantified in 
Figure 4.9F, using methods previously described18. 
 
DISCUSSION 
 Implantation requires the correct synchronization of embryo maturation and 
uterine receptivity.  When this process is altered, as is the case with IVF pregnancies, 
there are increased risks of adverse pregnancy outcomes including an increased risk of 
PE. BPH/5, a mouse model of PE, show profound placental defects that precede the 
development of PE-like symptoms later in gestation17, 18. Placental defects in PE have 
been associated with defects in trophoblast invasion and remodeling of maternal spiral 
arteries 16.  The trophoblast lineage is established in the pre-implantation period.  As 
such, the current study asked the question whether the placental defects in BPH/5could 
be traced back to the peri-implantation period.  This study systematically examined the 
peri-implantation period in BPH/5 mice, taking into account both embryo maturation 
and maternal endocrine signaling that determines the window of implantation. We 
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have found asynchronous maternal and fetal events that lead to implantation defects in 
this mouse model.  Implantation sites in BPH/5 are clustered, and show significant 
morphological and molecular defects compared to control C57s. Artificially 
synchronizing blastocyst competency and maternal endocrine signaling rescues many 
of these implantation defects, with beneficial effects on later placentation.  
BPH/5 mice showed a drastic delay in embryo maturation during the pre-
implantation period (Figure4. 1 and 4.2).  Close examination of related strains showed 
that this delay is unique to the BPH/5 inbred strain.  This suggests either an embryo 
deficiency in BPH/5 or the effect of a suboptimal oviduct or uterine environment.  
Several groups have highlighted the importance of the oviduct and uterine milieu in 
the development of the embryo23, 24. Interestingly, in superovulated mice, delayed 
embryo maturation is observed in the progression to the blastocyst stage and hatching 
kinetics in contrast to naturally cycling controls 25.  Additionally, stimulation of the 
oviductal environment had detrimental effects on embryo implantation and fetal 
viability, resulting in an IUGR phenotype and increased resorption rate in these  
mice 25, 26.   These traits show significant resemblance to BPH/5 phenotypes of embryo 
maturation delay, implantation defects, fetal demise and IUGR in this model.  Such 
striking similarities draws future work to examine the endocrine signaling at the time 
of ovulation, and a more thorough characterization of oocyte quality in these mice.     
 One of the most marked implantation phenotypes in BPH/5 mice was the 
clustering of embryos along the uterine horn. This was in contrast to evenly spaced 
embryos in control C57s as well as other related strains (Figure 4.3). Our embryo 
transfer experiments also highlight the coordinated role of both embryo and maternal 
components in the development of this defect, as clustering is only present when 
BPH/5 embryos are implanted in a BPH/5 mother (Figure 4.5).   The phenomenon of 
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embryo spacing can be a determinant of embryo success and survival.  Many 
polytocous species space implantation sites evenly within the uterus perhaps to 
maximize the maternal resources surrounding each embryo 27. Overcrowding of 
implantation sites has been linked to several placental defects 21, 28. The mechanism of 
embryo spacing however is largely unknown.  Studies using an inhibitor of 
myometrial contractions, relaxin, highlighted the role of maternal uterine contractions 
in separating/aligning the embryos prior to implantation29, 3031.  Additionally, the use of 
transgenic mice has greatly improved our molecular understanding of this  
process21,32-34. Recent work from the Arai lab demonstrates the involvement of 
lisophosphatidic acid (LPA) in embryo spacing21. LPA deficient mice show clustering 
of implantation sites, and treatment with an LPA agonist induces rapid uterine 
contractions in wild type mice, but not LPA deficient mice.  This highlights LPA as a 
mediator of the uterine contractions in embryo spacing 32.   Other candidates include 
Wnts where Mohammed and colleagues recently examined their role in potentially 
mediating uterine smooth muscle cell contraction33, 35.    Mice deficient in 
prostaglandin signaling, such as cPla2 knockout mice, also show defects in embryo 
spacing as well as delayed implantation rates 34. This highlights a potential functional 
link between delayed implantation and clustering of implantation sites.   Interestingly, 
Ptgs2, an enzyme downstream of cPLA2, is among the dysregulated genes in BPH/5 
implantation sites, implicating this pathway as a potential mediator of this 
implantation defect in BPH/5 mice.   
The pathway beginning with cPLA2, via Ptgs2 and ultimately prostaglandin 
signaling has received quite a bit of attention for its role in implantation and early 
decidualization events.  During implantation the uterine stroma undergoes decidual 
transformation where stromal cells proliferate and differentiated into decidual cells, 
ultimately becoming the maternal portion of the placenta 36 . This reaction is specific 
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to areas surrounding the implanting blastocyst.  Prostaglandins are thought to be 
involved in initial vascular changes by increasing vascular permeability as well as 
early decidualization 36.  The enzymes Ptgs1 and Ptgs2 (murine COX1 and COX2) 
mediate the conversion of arachadonic acid to downstream prostaglandin synthesis. 
Ptgs1 is the constitutively active isoform in the uterus, whereas Ptgs2 is inducible in 
response to cytokines and growth factors 37. In knockout Ptgs2 mice, reproductive 
effects include failure of blastocyst implantation and decidualization in some strains38.  
Interestingly, Ptgs2 has been demonstrated to affect the window of implantation in 
mice 34, 39. In studies using low doses of pharmacological inhibitors of both Ptgs1 and 
Ptgs2, implantation shifted later by more than 24hrs 39. This led embryos to implant 
out of the optimal window of implantation, leading to significant fetal loss later in 
pregnancy.     Additionally, mice with a null mutation in the upstream enzyme 
cytosolic phospholipase A2 (which produces the arachidonic acid substrate for Ptgs2), 
also show a shift in the timing of the window of receptivity, delayed implantation, 
abnormal uterine spacing as well as defects in fetoplacental growth and development34.  
Many of these implantation defects as a result of a shifting of implantation timing 
show marked similarities to BPH/5 implantation kinetics.  However, BPH/5 
implantation sites show an elevation in Ptgs2 compared to controls (Figure 4.8), which 
is not predicted by these previous studies.   A more thorough examination of Ptgs2 
signaling and localization within the implantation sites is warranted to resolve this 
discrepancy. 
 Histological analysis of BPH/5 implantation sites revealed morphometric 
defects, most notably the presence of a lumen in the implantation sites.   In rodents, 
the period of uterine receptivity is characterized by generalized edema as the uterine 
walls close around the blastocyst 40. This process is largely mediated by  
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progesterone 40 and estrogen41. As we have shown altered endocrine signaling in the 
implantation period (Figure 4.6), this may explain the incomplete closure of the 
uterine tissue surrounding the implantation site.  This period of implantation is also 
characterized by increased vascular permeability in uterine tissue surrounding the 
embryo, as well as the onset of decidualization. Interestingly, other mouse models 
where a persistent uterine lumen is present include models where NO signaling is 
pharmacologically altered 42, or VEGF signaling silenced 41, highlighting the 
importance of vasodilation in the uterine edema characteristic of this time.   The 
BPH/5 implantation sites also show reduced decidualization and embryo growth 
compared to controls.  Interestingly, the morphological parameters examined were 
similar between spaced embryos and those embryos in a cluster (Figure 4.4).  
Additionally, the molecular signature of all BPH/5 sites, irrespective of spacing, is 
similar (Figure 4.8).  This suggests that the clustering phenotype is a representation of 
global implantation defects.  
 Several of our implantation phenotypes are linked to aberrant pre-implantation 
maternal endocrine signaling.  Direct analysis of the ovarian steroids estrogen and 
progesterone revealed premature endocrine signaling, shifting the window of 
receptivity earlier in BPH/5 (Figure 4.6). This, when matched with delayed embryo 
maturation, leads to asynchronous implantation timing between embryo and uterus.  
The molecular profile of natural BPH/5 implantation sites shows significant defects in 
genes downstream of endocrine mediators (see Figure4.9 8). For example, Lif is a 
potent downstream target of estrogen signaling. In fact, an injection of LIF can be 
substituted for nidatory estrogen surge to elicit implantation in mice43, and Lif 
knockout mice are sterile due to implantation failure44.  Downstream mediators of 
progesterone signaling include amphiregulin45, and the immunophilin FKBP5246.    
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Each of these targets has a significant role in fertility and implantation success 44-46.  
As BPH/5 show significant dysregulation of all of these genes, this may play a role in 
our implantation defects in this model. 
 Over the past few decades, mice have proven to be an invaluable resource in 
the study of the various contributions to implantation and our knowledge of 
mammalian development20.    As we have demonstrated a lack of synchronization 
between embryo maturation and uterine receptivity in BPH/5, the use of the delayed 
implantation model has proved indispensible in examining the specific defects in this 
mouse strain.  By artificially prolonging uterine receptivity, we have allowed BPH/5 
embryos to mature in vivo, and then elicited implantation in a synchronized manner. 
By coordinating implantation events, we have resolved not only the proximal 
implantation defects such as clustering of implantation sites and the altered molecular 
signature of these implantation sites (Figure 4.8), but also later placental defects 
characteristic of this mouse model (Figure 4.9).  By synchronizing implantation 
events, BPH/5 placentae show improved invasion into the decidua, and more 
developed labyrinth and spongiotrophoblast layers compared to natural pregnancies, 
confirming our previous findings 18. This suggests that implantation defects in the 
natural pregnancy affect the trophoblast cell lineage, as these cells are critical in these 
processes 14, 15. This work highlights the importance of examining placentation defects 
by tracing events back to the peri-implantation period.    
 This study emphasizes the importance of the peri-implantation period in 
pregnancy success using a murine model of a relatively common pregnancy disorder, 
PE.  PE has long been characterized as a disease of placentation, but more recent 
theory suggests a deficiency at the time of implantation may be the origin of this 
disorder 16.  The BPH/5 mouse model of PE shows asynchronous implantation events 
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that cause implantation defects, leading to poor placental outcomes and fetal demise in 
this model.  Future work would examine the effect of rescuing implantation defects on 
the development of the maternal late gestational hypertension and proteinuria, the 
hallmark symptoms of PE. By focusing our efforts to better understanding of the peri- 
implantation cascade, greater improvements could be made in our understanding of 
the etiology of PE in women. 
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CHAPTER FIVE: 
DISCUSSION 
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Summary of Findings 
 Prior to this thesis, significant work had been carried out by Hoffmann and 
colleagues to define and characterize many aspects of the BPH/5 mouse model of pre-
eclampsia (PE).  Multiple phenotyping studies proved the presence of the hallmark 
maternal symptoms of PE, along with the placental pathology associated with human 
PE in the BPH/5 mice1, 2.  Initial studies found significant fetal demise as determine by 
necropsy, and poor fetoplacental outcomes including small litters of low birth-weight 
pups.  These studies were instrumental in establishing this inbred mouse strain as an 
important model for the study the pathogenesis PE. 
 Building on this, this thesis sought to answer three major questions: 1) Do 
BPH/5 mice show an angiogenic profile during pregnancy that mimics that of women 
who are at increased risk of developing PE? 2) What are some potential underlying 
causes of fetal demise and poor fetoplacental outcomes as determined by molecular 
profiling of BPH/5 fetoplacental units? 3) And finally, can the placentation defects 
previously characterized in BPH/5 be traced to the peri-implantation period? 
 In Chapter 2, we examined the role of angiogenic factors in the pathology of 
PE in BPH/5. Initially, we examined the levels of circulating angiogenic factors and 
found a significant decrease in factors VEGF and PGF in BPH/5 compared to controls, 
and that the decrease in these factors was independent of sFLT1 antagonism.  Though 
human studies show an increase in sFLT1 levels, these generally occur later in 
gestation.  Next we performed a gene transfer rescue study in which we delivered 
adenovirus encoding a diffusible isoform of VEGF early in pregnancy. This had 
significant effects on attenuating the development of the hallmarks of PE, as well as 
improving fetal outcomes in BPH/5.  Additionally, preliminary data suggests that the 
VEGF therapy acts at the level of the placenta by improving spiral artery remodeling. 
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 In Chapter 3, we examined the question of early fetal status in BPH/5. By 
using ultrasound-mediated scoring of implantation sites, we were able to identify three 
classes of fetoplacental units that differed based on various fetal status parameters.  
This served as a platform to examine at the molecular level why some implantation 
sites may survive to term, while others perish.  Even the healthiest BPH/5 embryos 
showed significant defects in cell adhesion and extracellular matrix remodeling 
pathways, which is not surprising given the placental defects present in this model. 
Interestingly, BPH/5 embryos also showed a defect in bone morphogenesis, a process 
very intimately linked to circulating angiogenic factors, highlighting our findings in 
Chapter 2.  Finally, the two most challenged fetoplacental classes showed global 
defects in embryo development as well as an increase in apoptotic genes, suggesting 
that these embryos are part of the group of embryos that perish during gestation. 
 Finally, in Chapter 4, we examined the peri-implantation period in BPH/5 to 
examine whether causes of the later placental phenotypes may have originated from 
defects at this stage.  Pre-implantation BPH/5 embryos showed a significant delay in 
their maturation compared to C57 controls. Additionally, this was juxtaposed against 
an implantation endocrine profile that is premature in BPH/5.  The combination of 
delayed embryo development with premature maternal hormonal signaling leads to 
implantation defects including abnormal morphology and spacing of implantation 
sites.  These defects can be rescued when embryo maturation and maternal endocrine 
signaling are synchronized artificially.  Excitingly, the fetoplacental units from the 
pregnancies with artificially synchronized implantation events also show significantly 
improved later fetoplacental phenotypes, including placental expansion and umbilical 
blood flow, compared to naturally mated BPH/5. 
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Proposed Model: 
 These studies have provided important advances in our understanding of the 
BPH/5 model and how some of these findings may translate to the human disease.  
The schematic in Figure 1 synthesizes the important findings from this thesis as well 
as highlights areas of future study. The discussion to follow will progress through each 
component of the figure. 
1) Asynchronous peri-implantation events 
 The studies presented in this thesis suggest that the pathological cascade in 
BPH/5 may begin as early as the pre-implantation period, a time point that had not 
been previously examined in this or other models of PE.  My studies have shown 
significant delays in BPH/5 embryo development prior to implantation and that these 
delays have significant repercussions on implantation (Chapter 4: Figure 1 and 3).   
Additionally, I examined the in vitro growth kinetics of embryos isolated from the 
point of fertilization onwards to check oocyte quality (Chapter 4: Figure2). The 
embryos progress from the fertilized oocyte stage to the 2 cell stage normally, 
suggesting no major compromise in oocyte integrity. The maturation delay in BPH/5 
embryos seems to begin around the progression from 4 to 8 cell stage.  My studies 
have defined the kinetics of this delay, but further characterization of genetic defects 
at this stage is definitely warranted.   Several candidates for stem cell and lineage 
development have been explored over the recent decades and may provide insight into 
the specific maturation delay observed in our studies.  As the BPH/5 embryonic delay 
seems to begin at the conversion from 4-8cell stage, one of the main targets expressed 
at that time is Oct43. The expression of this transcription factor increases at the 4-8cell 
stage where it is expressed in all nuclei. Interestingly, from this point forward, the   
156 
 
 
 
 
 
 
 
Figure 5.1: Schematic of the proposed pathological cascade in the development of 
PE in BPH/5.  Asynchronous maternal signaling and embryo maturation (1) leads to 
implantation defects including the presence of a persistent lumen (2).  The persistent 
lumen may alter the hypoxic state of the implantation site leading to impaired 
trophoblast differentiation, invasion and activation of immune cells.  This leads to 
inadequate spiral artery remodeling and altered hemodynamic characteristics (3).   The 
proximity of the implantation site to the lumen may have adverse effects on 
fetoplacental health (4). The lack of spiral artery remodeling impacts placental 
perfusion, and together with hemodynamic parameters(3) of the placenta leading to 
potential secretion of trophoblast debris, may contribute to the development of the 
maternal syndrome. 
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relative expression of this transcription factor within the cell determines its lineage: 
with the greatest expression leading to extra-embryonic endoderm and mesoderm 
lineages and lowest expression in trophectoderm cells, and a maintained expression 
level remaining part of the embryonic stem cell lineage3.  In Oct4 knockout models, 
blastocysts fail to form and cells show properties of trophectoderm lineages4.  An 
additional transcription factor, Nanog, shares expression in the embryonic stem cells 
with Oct45.  Interestingly, when this transcription factor is knocked out, all stem cells 
differentiate to a primitive endoderm phenotype6.  Numerous factors that determine 
the trophoblast cell lineage have been studied by Rossant and colleagues over the 
years.  A key factor includes Cdx2, one of the earliest acting trophoblast markers, and 
is suggested to be at the top of the hierarchy of transcription factors determining this 
fate5, 7. Cdx2 mutants are lethal at the preimplantation stage due to failure at the 
blastocyst stage7.  Later trophoblast lineage markers, including Eomes, are 
downstream of Cdx2 and confer post-implantation trophoblast lineages. Eomes 
mutants are lethal at the early post-implantation stage7, 8. Additionally, future studies 
should consider early markers of oocyte integrity such as MATER and Filia, proteins 
encoded by the maternal genome that are part of a subcortical maternal complex and 
aid in pre-implantation embryo development9, 10.  Interestingly, studies using null Filia 
embryos show delayed pre-implantation embryo development 11, highly reminiscent of 
BPH/5 kinetics.   I am confident that many of these targets will show differential gene 
expres+sion in BPH/5 embryos. Whether they reflect simply a kinetic shift or a 
differentiation defect would be very useful in studies moving forward. Though I tried 
to perform a molecular profile of BPH/5 pre-implantation embryos, our RNA 
extraction techniques and the tissue limitations for this kind of analysis, have proved 
challenging.  Though microarray strategies would be useful in identifying 
dysregulated targets, acquiring sufficient RNA from pre-implantation embryos for this 
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type of assay would be very difficult.  Future studies may consider immuno-staining to 
better characterize these embryo defects. 
 My studies have also examined the maternal role in implantation defects 
observed in BPH/5. Characterization of the time-course of maternal endocrine 
signaling through assaying estrogen and progesterone levels showed a shift in 
signaling that is earlier than C57 controls (Chapter 4: Figure 6).   This begs the 
question as to why this would happen in a strain that already shows delayed embryo 
maturation, especially since the combination of early endocrine signaling and delayed 
embryo maturation would give rise to implantation defects.  One might hypothesize 
that this is a compensatory mechanism; providing an early endocrine cue can perhaps 
accelerate embryo maturation at the expense of moderate implantation defects.    A 
number of studies have illustrated that estrogen signaling is the key event that leads to 
implantation 12-14. In the absence of estrogen surge, blastocysts hatch but remain 
dormant in the uterus until this signal is given13. This is the basis of the delayed 
implantation model, a technique very readily employed in the study of murine 
implantation. Estrogen signaling (mediated by Lif), is also required for blastocyst 
activation and its preparation for implantation 15-18. As this is such a potent signal for 
the final stages of blastocyst maturity, perhaps by providing an early cue (as in BPH/5 
mice), this may help accelerate the delayed embryo maturation in this strain.  This 
hypothesis can be tested by culturing BPH/5 embryos in vitro with varying amounts of 
estrogen in the media to see if the growth kinetics are accelerated due to this external 
stimulus.   
Linking pre-implantation defects to implantation defects 
 Stemming from the endocrine signaling and embryo maturation defects, my 
studies show an implantation defect in BPH/5. This defect most strikingly manifests as 
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clustering of implantation sites (Chapter 4: Figure3).However, upon further analysis, 
clustered embryos have similar morphological and molecular signatures (Chapter 4: 
Figure 4 and 7), suggesting that perhaps clustering is only a visual cue to a greater 
implantation defect affecting all BPH/5 implantation sites.  Studies not presented in 
this thesis tested the hypothesis that clustered implantation sites resulted in some of 
our previously scored Class II and III embryos (methods from Chapter 3).  These 
studies involved performing pontamine studies (e5.5) on anaesthetized mice to 
identify early implantation site spacing followed by recovery from this procedure and 
examination of fetoplacental health using ultrasound at e10.5.  Contrary to our 
hypothesis, Class I, II and III embryos were distributed among spaced and clustered 
implantation sites, with only a slightly increased incidence of Class II and III embryos 
in a cluster.   The cause(s) of clustering however is an important question that has seen 
very little study.  The spacing of implantation sites in litter-bearing species is 
important in maximizing the allocation of maternal resources per embryo19. Clustering 
of implantation sites has resulted in many placental defects such as hypertrophy, 
twinning and fetal demise 20-22. Potential mechanisms behind clustering include failure 
in maternal uterine contractions 23, 24, and roles for lisophosphatidic acid (lPA), 
cytosolic phopholipase A2 (cPLA2) and their downstream products 21, 25, 26. Alternative 
hypotheses include the role of Wnt signaling in explaining this phenomenon27, 28. Wnt 
pathways are transiently expressed in uterine smooth muscle prior to implantation 28, 
suggesting a potential role in uterine contractions used to separate blastocysts.  I 
would hypothesize that the clustering defect in BPH/5 is resulting from embryos 
implanting outside the receptive window of the uterus. I have demonstrated premature 
maternal endocrine signaling in BPH/5 mothers (Chapter 4: Figure 6), and that later 
implanting embryos are more likely to be in a cluster (Chapter 4: Figure 3).  This 
suggests that the embryos may be implanting outside the natural window of 
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implantation, perhaps a time when maternal contractions have stopped. This may lead 
to clustering of these implantation sites. Further examination of maternal uterine 
contractions is warranted in the peri-implantation period.  
 
2) Persistent Lumen 
 Morphometric analyses of implantation sites from BPH/5 embryos showed 
significant morphological differences in embryos compared to controls. Most striking 
is the persistence of a lumen in the implantation sites (Chapter 4 : Figure 4). When 
comparing the cross sections of implantation sites between BPH/5 embryos and C57 
controls, the location of the embryo with respect to the antimesometrial and 
mesometrial poles are similar, indicating that the location of implantation of BPH/5 
embryos in the uterus is normal.  The distance from the antimesometrial pole is 
denoted as a black arrow in Figure 5.1.      I believe the distance to the lumen is key to 
embryo survival in BPH/5 (red arrow). 
 Before we consider the effects of a persistent lumen during the implantation 
period, future studies may consider the causes of the lumen.  During normal 
implantation, this process is characterized by a time of generalized uterine edema, as 
the uterine walls close around the blastocyst 29. As a uterine event, it is governed by 
ovarian steroids used to coordinate uterine receptivity 29, 30. As we have demonstrated 
premature endocrine signaling in BPH/5, this process may be shifted as well, leading 
to an incompatible embryo-uterine cross-talk at this time. Other models where a 
persistent lumen is present involve defects in vasodilatory mediators such as nitric 
oxide and vascular endothelial growth factor, highlighting their importance in this 
process 30, 31.  It is interesting that VEGF may be a player at this time, as we have 
shown significant defects in VEGF signaling throughout the remainder of pregnancy 
(Chapter 2).     Numerous investigators have characterized several genes necessary for 
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implantation and decidualization including adhesion molecules, extracellular matrix 
remodeling factors, vasoactive factors, growth factors, cytokines, homeobox genes, 
cell cycle regulators, endocannabinoid signaling, and developmental genes (reviewed 
in Dey, 200432). Not surprisingly, many are downstream of estrogen and progesterone 
signaling including Lif, Fkbp52, Areg, Hoxa-10, cyclins D and E, Hif and potentially 
Vegf32-39.  In our studies, Fkbp52, Areg and Lif were dysregulated in BPH/5 
implantation sites, correlating with our premature endocrine signaling (Chapter 4: 
Figure 6 and 7). One can hypothesize that the signal for decidualization (linked very 
closely to implantation timing and endocrine-driven preparedness), is offset in BPH/5, 
leading to a decrease in the rapid proliferation of uterine cells causing  a decreased 
area of decidualization as shown in Chapter 4 Figure: 4.  Further characterization of 
the spatial distribution of decidualization targets including BMP2, PTGS2 and PTGS1 
(murine Cox2 and Cox1), and perhaps additional targets involved in uterine edema 
including VEGF and NO signaling, may hint at a mechanism surrounding the presence 
of the uterine lumen. 
 
Linking persistent lumen to the altered state of hypoxia and impaired trophoblast 
differentiation 
 How then does the persistent lumen provide the initiating cascade in the 
pathology of PE in BPH/5? In human pregnancy, the early post-implantation stage of 
the utero-embryo milieu is characterized by a period of hypoxia 40, 41. Endovascular 
cytotrophoblast cells migrate and plug maternal spiral arteries resulting in a low 
oxygen environment.  After the plugs are dislodged at 12 weeks, the oxygen tension 
rises roughly threefold (2.5% to 8.5%)42.  Early trophoblast differentiation and 
proliferation requires a hypoxic environment.  Many of the differentiation pathways 
are governed by hypoxia-inducible factor-1α (HIF-1α) mediated pathways43.  Whereas 
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hypoxia stimulates the proliferative phenotype of trophoblast cells, increased oxygen 
concentrations drive differentiation towards a more invasive phenotype44.  Very little 
is known about the oxygen environment in early murine implantation sites.  A study 
by Pringle and colleagues used the hypoxia marker primonidazole and showed levels 
of hypoxia in implantation sites from e5.5-7.5 mice45. I believe that the presence of the 
lumen may alter the hypoxic environment necessary for these essential early events.   
To test this hypothesis, a similar strategy to the study by Pringle and colleagues would 
be adopted, where primonidazole would be administered to BPH/5 and C57 mice and 
e5.5-7.5 implantation sites examined.   That would tell us whether the lumen altered 
the hypoxic state of the implantation site.  Additionally, hypoxia-sensitive targets such 
as HIF1α and its downstream genes Vegf and the glucose transporter Slc2a1 need to be 
examined in implantation sites. In murine studies, oxygen tension had a significant 
effect on trophoblast lineage specification, as demonstrated by an increase in 
spongiotrophoblast cells when ectoplacental cone explants were grown in low oxygen 
environment45.  If the lumen in BPH/5 mice altered the hypoxia sensitive genes, future 
studies should also consider the effects on trophoblast lineage specification. 
 Hypoxia, oxidative stress and trophoblast lineage abnormalities are each 
associated with human PE.  Preeclamptic placentae show an abundance of 
proliferative intermediate trophoblasts 46. This suggests an inadequate conversion at 
~10-12weeks to the invasive phenotype perhaps resulting from prolonged hypoxia 
exposure, leading to decreased invasiveness and spiral artery remodeling.  The area of 
early implantation trophoblast lineage defects in PE pregnancies remains entirely 
unknown.  This is where murine models will be invaluable.  
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Linking persistent lumen to shallow invasion of trophoblast cells 
If the hypothesis that the persistent lumen was altering trophoblast 
differentiation and proliferation were true, it follows that this would impact the 
invasion of these cell types into the maternal uterine tissue. Shallow invasion is both a 
characteristic of early onset PE placentae as well as in the BPH/5 model 2, 47.   
Excitingly, my research shows that when the implantation period is synchronized 
artificially, we rescue the shallow invasion phenotype observed in BPH/5 (Chapter 4: 
Figure 8).   This would suggest that by resolving implantation defects, we have 
provided the optimal conditions for trophoblast differentiation, and these cells invade 
the maternal decidua to the same depth as the control strain. 
 
Linking persistent lumen to decreased activation of immune cells 
A consequence of shallow invasion may also be poor recruitment and 
activation of immune cells necessary for the early placentation and invasion processes. 
Uterine NK cells as well as macrophages are an important source of angiogenic factors 
as well as cytokines necessary to promote trophoblast invasion 48, 49.  Preliminary data 
from our VEGF studies shows a significant improvement in spiral artery remodeling 
in BPH/5 when treated with VEGF (Chapter 2: Figure 7).  A potential reason for this 
improvement is that we are supplementing a system with VEGF where this might 
normally be provided by NK cells. Therefore, we may be bypassing the deficient NK 
cell population by VEGF administration, thus rescuing the process of spiral artery 
remodeling.  A thorough examination of the immune cells, especially the natural killer 
cells, would greatly benefit our understanding of the immunologic role in the placental 
defects and PE symptoms in BPH/5.  
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As I have observed a significant defect in implantation in BPH/5, moving 
forward, microarray work may help identify some of the key players in these specific 
defects of embryo clustering and the presence of the lumen.  Microarray work, 
however, has its limitations in that the volume of data acquired from these 
experiments often poses challenges for future analyses. Ideally, one would choose the 
most basic starting material to examine genetic differences. Following that theory, the 
initial defects that we see are in the pre-implantation embryo. However, acquiring 
sufficient RNA from 4/8cell or morula stage embryos for a microarray would be 
nearly impossible.  Therefore we should consider early implantation sites as our 
microarray starting material.  As we have shown, implantation sites have pathology of 
persistent lumen, decreased decidualizaion and embryo growth as well as the 
clustering of these implantation sites (Chapter 4: Figure 3, 4, 7).  The implantation site 
itself, however is large enough to provide enough RNA for microarray studies. In our 
case, early implantation samples would presumably show defects in decidualization, 
trophoblast differentiation and potentially hypoxia sensitive genes.  Additionally, 
when thinking of the application of microarray generated targets, the goal is to provide 
a means of rescuing a genetic defect. In a placentally-driven disease such a PE, we 
would want our intervention to happen as early as possible, if not the pre-implantation 
period, then early implantation.   Lentiviral mediated targeting of trophoblast cells, is 
an exciting new technology that would enable the rescue of specific placental defects 
50. By infecting pre-implantation embryos with at the blastocyst stage with lentiviral-
encoded targets, recent studies have shown the specific localization of these targets to 
trophoblast lineages, with no non-specific infection of embryo lineages51, 52. This 
technology is being developed in our laboratory and will be incredibly valuable in this 
model. 
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5.3 Spiral artery remodeling and hemodynamic outcomes   
Previous work in our lab has demonstrated defects in spiral artery remodeling 
in the BPH/5 model.  My studies have shown that even the healthiest embryos (Class 
I), and the most likely to survive, exhibit these defects.  Trophoblast defects in 
maturation and proliferation whether due to lack of sustained hypoxia during 
development caused by a persistent lumen during implantation, or other factors, can 
lead to decreased invasion and activation of immune cells leading to a lack of spiral 
artery remodeling.   Spiral artery remodeling defects is one of the hallmark features of 
human PE placentae 47. The obvious consequence of reduced spiral artery remodeling 
is reduced blood flow to the intervillous space. However, recent hypotheses suggest 
that it is not simply the quantity of blood flow but the quality of blood flow that is 
problematic53, 54.  In the normal placenta, spiral arteries are dilated leading to increased 
blood flow. The blood flow however is under low pressure and is thought to gently 
bathe the intervillous space. This is beneficial for the exchange of nutrients across the 
delicate fetal/maternal interface.  Diffusion rates are improved when the distance 
between two compartments is minimized. Therefore, in pregnancy, a thin layer (the 
syncytiotrophoblast) separates maternal and fetal circulations, allowing oxygen, 
nutrients and waste products to be freely diffused53. Additionally, a positive pressure 
differential favoring a fetal to maternal direction results in higher pressures in the fetal 
capillaries compared to the intervillous space. This pressure gradient prevents 
compression of fetal vessels55.  This is under marked contrast from the PE placentae, 
where the arteries are not remodeled, and lead to less blood flow but under a 
significantly higher pressure56. Therefore, the beneficial fetal to maternal pressure 
gradient is lessened, which could lead to fetal nutrition defects.  Additionally, instead 
of smoothly bathing the intervillous space, the “jet-like” blood flow can cause 
significant damage to the delicate syncytiotrophoblast layer53, 57.  This can lead to 
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increased levels of turnover and sloughing of synctiotrophoblast knots into the 
maternal circulation53, 58. The phenomenon of increased trophoblast debris in the 
maternal circulation has been correlated with increased risk of PE, through mediation 
of the immune response58. 
A thorough examination of spiral artery remodeling in BPH/5 is currently 
being examined in the lab with the use of vascular casting and MicroCT. This work 
will provide a marked improvement from histological examination as it will consider 
the vessels in the entire placental bed, instead of single vessels in a histological 
section. We will be able to examine the number of spiral arteries per placenta as well 
as the volume of maternal blood flow to the placenta, providing a unique perspective 
to the placental perfusion question.  Additionally the specific 3D architecture of the 
vessel bed as well as individual measures of spiral artery tortuosity will further our 
ability to characterize the placental defects of BPH/5.  Future work might also 
examine the vasculature differences from the pregnancies where implantation was 
synchronized artificially.  As we have rescued invasion defects in placentation, 
perhaps we have also improved some of the vasculature defects in this model. 
Trophoblast and syncytiotrophoblast turnover is not something that has been 
examined in BPH/5. With the current hemodynamic theory, this would be an 
interesting venue to examine.  Examining the quantity of trophoblast debris in the 
maternal circulation, as well as the known inflammatory cytokines known to be 
activated by this process (IL-6), would give a systemic inflammatory perspective to 
placental stress.  Flow cytometry protocols have been established for the 
measurements of these syncytiotrophoblast knots in circulation59. It would be 
interesting to quantify not only the number of particles shed, but the nature of these 
particles, whether they have been generated by apoptotic or necrotic pathways.  Chen 
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and colleagues have demonstrated an abundance of particles generated by necrotic 
pathways that induce an inflammatory response in PE pregnancies58. 
 
5.4  Variation in embryonic health status 
Linking persistent lumen to variations in embryonic health status. 
 We know that implantation defects are present in BPH/5 and that there is also a 
variation in fetoplacental health as characterized by ultrasound at e10.5.  The spacing 
between the implantation site and the lumen may also lead to the variation in 
fetoplacental health.  In fact, in both systems where a uterine lumen is present (VEGF 
silencing and NO signaling alteration), significant effects were found in pregnancy 
success30, 31. If this hypothesis is true, then the embryos closest to the lumen would 
have significant trophoblast differentiation defects leading to global development 
attenuation, perhaps as reflected in Class III and ultimately fetal demise in these 
embryos. In contrast, the embryos furthest from the lumen, may show improved fetal 
outcomes as reflected in Class I, but maintain the trophoblast driven placental defects 
known in this model, resulting from the suboptimal implantation environment 
One strategy for determining whether there is a link between embryo-lumen 
spacing and the fetoplacental variation in BPH/5 would be the use of the viral strategy 
to target individual embryos with a specific marker (LacZ or GFP). These labeled 
embryos would then be implanted in a pseudopregnant female and the implantation 
characteristics would be examined.   These experiments would help test many of the 
hypotheses generated to date. Initially, one would label a specific set of embryos 
(either the most mature, or least mature). For the purpose of this discussion, let us 
consider labeling the most mature embryos with an adenovirus encoding LacZ.  We 
hypothesize that the most mature embryos implant the farthest from the lumen, and 
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become what we consider Class I embryos (the healthiest). Therefore, we would 
examine the implantation sites of all embryos (both labeled mature embryos, and 
unlabeled immature embryos) for the distance of the embryo to the lumen and co-
staining for the presence of LacZ.  In parallel, the same viral mediated labeling would 
be performed but these pregnancies would be allowed to continue until e10.5.  
Embryos could then be scored with the ultrasound, and subsequently stained for LacZ 
activity to correlate the health of the embryo with the presence of absence of the 
marker.  This would be an important set of experiments highlighting the effects of 
embryo proximity to the lumen on embryo maturation and implantation defects, as 
well as linking those implantation defects to later fetoplacental health.  A challenge to 
these experiments is that they would require embryo transfers (to isolate and infect 
embryos, then implant into pseudopregnant females). This procedure adds its own set 
of complications (success rate, shifted blastocyst and maternal timing). 
 
5.5 Linking it all together: thoughts on the development of PE in BPH/5. 
 In Chapter 4, I examined the implantation defects in a mouse model where 
placentation defects are also present2.  In the final figure of Chapter 4 (Figure 8), I 
have demonstrated the effects of coordinating implantation events on placentation.  
Excitingly, by synchronizing implantation, placentation defects of shallow trophoblast 
invasion are rescued in this model.  How defects in placentation are linked to the 
development of PE is still a major unknown in the study of pre-eclampsia. Many 
defects in placentation are shared with IUGR pregnancies, and yet some women 
develop PE while others have relatively uncomplicated pregnancies.    A common 
theory is that there is a threshold effect; that maternal constitutional factors, in 
combination with placental stress, may take an uncomplicated pregnancy to a PE 
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pregnancy.  Ultimately, the study of the link between placental defects and maternal 
symptomology would definitely provide an invaluable step forward in understanding 
this disease. 
 Placental samples at term in patients and animal models have provided us an 
important starting point to examine some of cascades that may lead to the 
development of PE.   Unlike other rodent models of PE, BPH/5 exhibits many of these 
placental defects early in gestation, and provides a unique tool for the linking of 
placental defects to the development of the maternal syndrome.  Placental perfusion 
defects are present in PE pregnancies47.  How these defects are produced may provide 
insight into how placental perfusion is linked to PE symptomology.  The role of 
diminished angiogenic factors have been shown to play an important role in the 
development of PE symptoms in various rodent models60, 61, including this study in 
BPH/5 (Chapter 2).  These factors have both local and systemic effects, by being 
instrumental in placental maternal vessel remodeling, and systemic effects of altering 
global vascular reactivity and kidney function. 
 Poor placental perfusion is very closely linked to shallow invasion of 
trophoblast cells into the maternal uterine tissue. This can be mediated by several 
immune cells. Recently, studies show that autoantibodies to the angiotensin 1 receptor 
(AT1-AAs) have significant effects of diminishing trophoblast invasion (mediated by 
plasminogen activator inhibitor-1)62, and also have the capability for inducing 
hypertension and proteinuria in rodent models63. This is also a promising candidate 
that has both placental and systemic targets. 
 Recent work from our group links placental oxidative stress to the 
development of PE in BPH/5. Attenuation of this placental ROS damage through 
Tempol treatment also suggests a link driven by oxidative stress and the development 
of PE in BPH/564.   
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 One of the most promising links between placental stress and maternal 
systemic immune activation is the shedding of trophoblast knots.  This provides a 
definitive link between perfusion defects and hemodynamic results, leading to 
increased placental debris.  This overwhelms the maternal immune cell capabilities to 
dispose of the debris, leading to a global immune and increased endothelial cell 
activation53, 58, 65. 
 Finally, in BPH/5 we show significant fetal demise throughout gestation in a 
fraction of the embryos in a litter 1, 2(Chapter 3). Though the links between this fetal 
demise and the development of PE symptoms is less clear, it cannot be ruled out.   
Though there are undoubtedly links between a distressed embryo and the maternal 
environment, it is not advantageous to respond to such stimuli that may lead to 
compromise of the remaining litter.    However, apoptotic remains of resorbed 
implantation sites may contribute to an already overwhelmed systemic inflammatory 
response.    
 
5.6 Perspectives: 
 This thesis has advanced our understanding of the development of PE in 
BPH/5 mice.   These studies have provided important mechanistic insights into 
pathological events observed in BPH/5 at different gestational stages.  Microarray 
work has examined the molecular signature of BPH/5 fetoplacental units and provides 
some clues as to the reason some of these embryos perish.  We have elucidated the 
role of angiogenic factors in the development of the symptomology of PE in BPH/5, 
and illustrated how closely our model resembles the human condition in this regard. 
Finally, and most importantly, this thesis argues for a shift in focus on the initiation of 
the PE cascade to the peri-implantation period.  By concentrating future studies to this 
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timeframe, we may provide an important intervention early in the development of PE, 
thereby preventing rather than treating an established disorder.   
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